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Pancreatic beta cell specification is a complex process, requiring proper function of 
numerous transcription factors.  Nkx2.2 is a transcription factor that is crucial for beta 
cell formation, and is expressed early and throughout pancreatic development.  Nkx2.2
-/-
 
mice display complete loss of the beta cell lineage and defects in the specification of 
other endocrine cell types, demonstrating the importance of Nkx2.2 in establishing proper 
endocrine cell ratios.  Recent studies have also demonstrated a role for Nkx2.2 within the 
mature beta cell to maintain identity and function.   
This thesis work investigated the timing of pancreatic beta cell specification and the 
mechanism of this process.  In these studies, Nkx2.2 was ablated specifically within the 
Ngn3-expressing endocrine progenitor population in vivo.  These mice displayed defects 
similar to Nkx2.2
-/-
 mice.  Surprisingly, the disruption of endocrine cell specification did 
not require loss of expression of multiple essential transcription factors known to function 
downstream of Nkx2.2, including Ngn3, Rfx6, and NeuroD1.  While these factors are all 
necessary for beta cell specification, their preserved expression did not rescue beta cell 
formation.  ChIP-Seq analyses also revealed co-occupancy of Nkx2.2, Rfx6, and 
NeuroD1 near endocrine-related genes, suggesting Nkx2.2 may cooperate with its 
downstream targets to regulate beta cell fate.  These results have revealed a unique 
requirement for Nkx2.2 during a critical window of beta cell development.   
 
In addition, the role of a conserved domain of Nkx2.2, the specific domain (SD), was 
assessed using Nkx2.2
SDmutant
 mice.  Transcriptional profiling of Nkx2.2
SDmutant
 endocrine 
progenitors revealed a critical role for the SD domain in regulating the transcription of 
endocrine fate genes early in the process of endocrine differentiation.  In addition, beta 
cell-specific deletion of the Nkx2.2 SD domain resulted in hyperglycemia, glucose 
intolerance and dysregulation of beta cell functional genes.  This suggests the SD domain 
is important for mediating Nkx2.2 function within the beta cell to maintain glucose 
homeostasis. 
Together, these results have elucidated a critical developmental window for beta cell 
specification and demonstrated an essential role for Nkx2.2 and specifically its SD 
domain in this process.  Furthermore, these studies suggest that beta cell transcription 
factors may also regulate endocrine fate in a combinatorial manner, and exert changes 
within the endocrine progenitor lineage.  These findings have provided us with a better 
understanding of in vivo pancreatic development, and will improve current research 
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Diabetes is a disease characterized by elevated levels of blood glucose.  The pancreatic 
endocrine compartment is essential for maintaining the blood glucose homeostasis of an 
organism.  Defects present in the endocrine compartment, specifically within the insulin-
producing beta cells, can result in hyperglycemia and lead to diabetes.  Diabetes was considered 
to be the seventh leading cause of death in 2010.  In the United States, 9.3% of the population 
was afflicted with diabetes in 2012 (CDC, 2014).  Worldwide, there is an estimated 415 million 
people currently living with diabetes.  With increasing prevalence, this number is expected to 
reach 642 million people in the year 2040 (IDF, 2015). 
Diabetes can be classified as type 1 diabetes (T1D), type 2 diabetes (T2D) or gestational 
diabetes.  T1D is caused by autoimmune attack of the pancreatic beta cells, leading to beta cell 
death and insufficient insulin production.  T1D is frequently diagnosed in children in their mid-
teens (CDC, 2014).  Cases of T1D are thought to comprise 5% of the total number of people 
diagnosed with diabetes (CDC, 2014).  T2D typically arises from insulin resistance and beta cell 
exhaustion.  T2D accounts for 90-95% of the cases of diabetes (CDC, 2014).  Lastly, gestational 
diabetes occurs in pregnant women.  It is typically diagnosed in the second or third trimester and 
is characterized by elevated levels of blood glucose (CDC, 2014).  It is estimated that 2-10% of 
pregnant women will develop gestational diabetes, with most cases resolving after childbirth 






There are numerous comorbidities that can occur as a consequence of diabetes.  These include 
cardiovascular diseases: heart attack and stroke, high blood pressure, and high cholesterol (CDC, 
2014).  Diabetes can also lead to kidney disease and failure, requiring dialysis or transplant.  In 
2011, 44% of new kidney failure cases in the U.S. were caused by diabetes (CDC, 2014).  In 
addition, blindness can result from diabetic retinopathy.  Neuropathy can also occur, sometimes 
resulting in amputation, typically of the lower-limbs (CDC, 2014; IDF, 2015).  In the U.S. alone, 
it is estimated that $245 billion USD was spent in 2012 on direct and indirect costs of diabetes 
healthcare (CDC, 2014). 
Current treatment options for people with diabetes focuses on maintaining glucose regulation and 
preventing hyper- or hypo-glycemia.  Exogenous insulin injections and numerous medications 
are currently being used as treatment.  In addition, artificial pancreata, islet transplants, and in 
vitro beta cell differentiation protocols are under development as diabetic therapies.   
Treatment for T1D patients involves delivery of exogenous insulin through a pump or injection 
(CDC, 2014; IDF, 2015).  This requires close monitoring of blood glucose throughout the day to 
ensure proper regulation.  For people with T2D, there are numerous medications that can be 
used, such as biguanides and sulfonylureas (IDF, 2015).  The most commonly used medication is 
metformin, a biguanide drug (Inzucchi et al., 2012).  Metformin acts by decreasing hepatic 
glucose synthesis and does not increase the risk of hypoglycemia (Bailey and Turner, 1996; 
Inzucchi et al., 2012).  Sulfonylureas increase insulin secretion from the pancreas (Bryan et al., 
2005; Inzucchi et al., 2012).  In addition, GLP-1 analogues or DPP-4 inhibitors can be used to 






Health Interview Survey, between 2010 and 2012, 14% adults with diagnosed diabetes were 
taking insulin only, 14.7% were taking both insulin and oral medication, and 56.9% were taking 
oral medication only (CDC, 2014). 
In recent years, progress has been made in the development of an artificial pancreas (Battelino et 
al., 2015; Nimri and Phillip, 2014; Peyser et al., 2014).  This system involves continuous glucose 
monitoring (CGM), calculation of appropriate insulin dosage, and automatic administration of 
insulin through an insulin pump (Deiss et al., 2006; Pickup 2012).  A major concern of the 
artificial pancreas is the incidence of acute hypoglycemia.  This can have serious detrimental 
effects, such as seizures, loss of consciousness, or death (Peyser et al., 2014).  To decrease the 
risk of hypoglycemia, insulin pump suspension is used to block insulin delivery when the CGM 
detects glucose at a certain threshold (Bergenstal  et al., 2013; Davis et al., 2015; Ly et al., 2013).  
While the first artificial pancreas models were equipped with insulin delivery only, efforts are 
being made to incorporate both insulin and glucagon administration to enable counter regulation 
and precise glycemic control (Haidar et al., 2013). 
Cadaver-derived islet transplants have also been successfully performed, resulting in insulin 
independence (Ryan et al., 2005; Shapiro et al., 2000).  However, this procedure is invasive and 
requires immunosuppression, which can cause ulcers and anemia (Ryan et al., 2005).  In 
addition, there is limited availability of islets for transplantation (Sheehy  et al., 2003).  Recent 
efforts are directed at increasing islet yield and improving islet engraftment (Yokoi et al., 2016). 
A burgeoning area of research has focused on the in vitro differentiation of pancreatic beta cells 






induced pluripotent stem cells (iPSCs).  A major challenge in this field of research is to 
differentiate cells that are monohormonal and fully functional.  Prior to 2014, the insulin-
expressing cells produced in vitro (hereinafter referred to as “beta-like cells”) co-expressed other 
pancreatic hormones, did not release insulin in response to glucose, and their transcriptional 
profiles more closely resembled those of immature beta cells than mature beta cells (D'Amour et 
al., 2006; Hrvatin et al., 2014; Kroon et al., 2008; Zhang et al., 2009).  In the last few years, there 
have been major advancements in this area of research.  By mimicking the events that occur 




 co-positive stage 
(see below), researchers were able to differentiate monohormonal beta-like cells with greater 
efficiency (Nostro et al., 2015).  To date, the transcriptional profiles of beta-like cells more 
closely resemble that of mature primary beta cells and are responsive to glucose (Pagliuca et al., 
2014; Rezania et al., 2014); however, the protocol still requires additional optimization.  
Differences in the transcriptional profiles of in vitro differentiated beta-like cells compared to 
adult primary beta cells still remain, possibly reflecting incomplete differentiation (Pagliuca et 
al., 2014).  In addition, these beta-like cells require both vascularization and isolation from the 
immune system to function and survive in vivo following transplantation.  Immunoisolation 
technologies are currently being developed using polymer-encapsulation (Vegas et al., 2016).  It 
will be necessary to optimize these advancements before in vitro beta cell differentiation and 






Pancreas Development and Establishment of Endocrine Cell Fate 
The mature pancreas consists of three main compartments:  exocrine, ductal, and endocrine.  The 
exocrine compartment is comprised of acinar cells responsible for the synthesis of digestive 
enzymes.  Ductal cells form networks connected to acinar cells and transport digestive enzymes 
to the duodenum.  The endocrine compartment regulates glucose homeostasis.  It is comprised of 
endocrine cells which form highly vascularized clusters, called islets of Langerhans.  The adult 
pancreas contains four types of endocrine cells, each type producing a single hormone:  insulin-
producing beta cells, glucagon-producing alpha cells, somatostatin-producing delta cells, and 
pancreatic polypeptide-producing PP cells (Slack, 1995).  Two additional endocrine cell types 
are confined to embryonic development:  ghrelin-producing epsilon cells and gastrin-producing 
G cells (Arnes et al., 2012a; Prado et al., 2004; Suissa et al., 2013). 
Murine pancreas development can be first observed morphologically at embryonic day (E)9.5.  
Two pancreatic buds emerge from the foregut endoderm, the dorsal pancreatic bud and ventral 
pancreatic bud.  The dorsal bud forms from the dorsal foregut endoderm at E9.5, while the 
ventral bud can be first observed at E10 from the ventral foregut endoderm (Pan and Wright, 
2011).  These buds undergo growth via cell proliferation, plexus formation and remodeling.  The 
dorsal and ventral buds eventually fuse together to form a continuous organ beginning at 
approximately E11.5 (Pan and Wright, 2011; Villasenor et al., 2010).  During this time of 
epithelial remodeling, the cells undergo tip-trunk compartmentalization, with cells in the “tip” 
region destined to become acinar cells, and cells of the “trunk” region restricted to endocrine or 






undergo a process similar to epithelial-mesenchymal transition (EMT) as they delaminate and 
migrate from the epithelial trunk, eventually coalescing to form islets of Langerhans (Fig. 1-1) 
(Rukstalis and Habener, 2007). 
Pdx1
+
 pancreatic progenitor cells 
Numerous transcription factors expressed during pancreas development have been identified, and 
their functional roles elucidated.  Pancreatic and duodenal homeobox 1 (Pdx1, aka IPF1 or STF-
1) is expressed in the pancreatic progenitor population.  These Pdx1
+
 cells first arise within the 
foregut endoderm beginning at E8.5, just prior to initial bud formation (Guz et al., 1995; Ohlsson 
et al., 1993).  Lineage tracing studies with Pdx1-Cre and Pdx1-CreER alleles in mice have shown 
that Pdx1
+
 cells give rise to all cell types in the mature pancreas: exocrine, ductal, and endocrine 
cells (Gu et al., 2002; Herrera, 2000).   
While Pdx1 is a specific marker of the developing pancreas, studies have also found that Pdx1 
expression is functionally essential for pancreas formation.  Pdx1
-/-
 mice display pancreatic 
agenesis and die shortly after birth (Jonsson et al., 1994; Offield et al., 1996).  Minimal 
pancreatic buds are capable of forming in Pdx1
-/-
 mice; however, there is little outgrowth or 
plexus remodeling (Offield et al., 1996).  This demonstrates the specificity and requirement of 
Pdx1 for pancreas development. 
Ectopic Pdx1 expression in chick embryos using in ovo electroporation has also demonstrated 
that Pdx1 is sufficient to repress intestinal, stomach, and liver differentiation markers.  In these 
experiments, Pdx1 expression was induced more broadly throughout the developing endoderm, 






were repressed, pancreatic endocrine cells did not form.  There were no insulin-producing beta 
cells or glucagon-producing alpha cells present in the ectopic Pdx1 region, indicating additional 
factors are required for endocrine cell specification (Grapin-Botton et al., 2001).   
The Pdx1
+
 pancreatic progenitor population is also critical for and directly related to final organ 
size.  Stanger et al. (2007) found that the Pdx1
+
 population present between E8.5 and E12.5 is 
essential for pancreas formation.  They also found a complete lack of compensative growth, 
suggesting that final organ size is determined by factors intrinsic to the pancreatic progenitor 
cells (Stanger et al., 2007).   
While these developmental studies have been conducted in mouse models, the function of Pdx1 
appears to be conserved in humans.  Stoffers et al. (1997) identified an inactivating mutation in 
exon 1 of PDX1, Pro63fsdelC, which was associated with pancreatic agenesis in the patient 
(Stoffers et al., 1997b).  Another mutation in PDX1 has been found, resulting in a cytosine 
deletion.  This mutation was linked to diabetes (maturity-onset diabetes of the young, “MODY”) 
and identified PDX1 as a novel genetic locus associated with diabetes, known as MODY4 
(Stoffers et al., 1997a).  A compound heterozygous mutation was identified in the homeobox of 
PDX1 in exon 2 and was also associated with pancreatic agenesis (Schwitzgebel et al., 2003).  





 endocrine progenitor cells 
Following tip-trunk compartmentalization, there are two waves of endocrine cell differentiation 






Wright, 2011).  These early endocrine cells are typically glucagon-producing alpha cells (Pictet 
et al., 1972).  The second wave of endocrine cell differentiation occurs from E13.5 to E18.5, and 
is the major window of endocrine cell formation (Pan and Wright, 2011).  Epsilon cells appear 
beginning at E10.5 (Prado et al., 2004) and G cells at E12.5 (Suissa et al., 2013).  Beta cells, 
delta cells, and PP cells begin to arise at E13.5, E15.5, and E18.5, respectively (Pictet et al., 
1972; Slack, 1995).  However, the initial formation of PP
+
 cells has been controversial due to 
potential antibody cross reactivity with neuropeptide Y (Npy) and peptide YY (Pyy).  Some 
studies report PP expression as early as E10.5 and others report PP
+
 cells present only after birth 
(Herrera et al., 1991; Jorgensen et al., 2007; Teitelman et al., 1993; Upchurch et al., 1994).  
Towards the end of embryogenesis, pancreatic beta cells undergo proliferation to increase beta 
cell mass (Bouwens and Rooman, 2005), and endocrine cells cluster together to form compact 
islet structures (Herrera et al., 1991; Pictet et al., 1972). 
In the expanding epithelial trunk domain, a subset of Pdx1
+
 cells begin to express Neurogenin 3 
(Ngn3, aka Neurog3), the first marker of endocrine cell differentiation (Jensen et al., 2000a; 
Schwitzgebel et al., 2000).  After Ngn3 expression is initiated, these cells become post-mitotic 
(Gu et al., 2002; Jensen et al., 2000a; Miyatsuka et al., 2011).  Ngn3
+
 cells are thought to 
undergo EMT-like delamination and migration (Fig. 1-1) (Gouzi et al., 2011; Rukstalis and 
Habener, 2007), after which Ngn3 is downregulated, and expression of one of the pancreatic 
hormones is activated (Gradwohl et al., 2000; Gu et al., 2002; Schwitzgebel et al., 2000).  
Lineage tracing experiments using Ngn3-CreER have shown that Ngn3 expressing cells give rise 
to all of the endocrine cell types and do not give rise to ductal cells (Gu et al., 2002; Heller et al., 








 cells corresponding with the major wave of endocrine cell differentiation occurring at 
approximately E15.5 (Schwitzgebel et al., 2000). 
Initial expression of Ngn3 appears to be controlled by Notch signaling, possibly through a 
mechanism of lateral inhibition.  There are numerous Notch ligands and receptors expressed in 
the pancreatic epithelium during development (Jensen et al., 2000b; Lammert et al., 2000).  
Studies manipulating Notch signaling have elucidated a functional role in endocrine fate 
specification.  Delta-like gene 1 (Dll1) and RBPJk are both components of the Notch pathway.  
Mutant Dll1 and RBPJk mice are embryonically lethal at E18.5-9.5 and E10-12, respectively.  
However, early analysis of endocrine cell specification show that both mutants exhibit increased 
Ngn3
+
 cell numbers.  Dll1 mutant mice also show decreased pancreatic bud size (Apelqvist et al., 
1999).  In mice deficient for Hes1, a downstream factor of Notch signaling, there is accelerated 
endocrine differentiation, particularly of the alpha cell lineage, at the expense of the other 
pancreatic cell types and pancreas organ size (Jensen et al., 2000b).  These findings suggest that 
Notch signaling may determine cell fate choice between endocrine and ductal lineages within the 
trunk epithelium. 
Ngn3 plays a pivotal function in endocrine specification; it is essential for the formation of all of 
pancreatic endocrine cell types.  Ngn3
-/-
 mice display complete loss of the endocrine cell 
populations: alpha, beta, delta, epsilon, PP and G cells (Gradwohl et al., 2000; Heller et al., 2005; 
Suissa et al., 2013).  This disruption of endocrine specification results in perinatal lethality due to 
hyperglycemia (Gradwohl et al., 2000).  There is no increase in apoptosis, suggesting the 






findings demonstrate a strict requirement for Ngn3 to allow endocrine cell fate commitment.  
While Ngn3 is required for endocrine specification, it is not known when endocrine cell fate is 
determined.  This process may be occurring early within the Pdx1
+
 pancreatic progenitor, or it 
may be occurring later in the Ngn3
+
 endocrine lineage.   
The importance of Ngn3 for islet cell specification may be conserved in human pancreas 
development as well.  In a case of permanent neonatal diabetes, compound heterozygous point 
mutations were identified in NGN3, with each mutation capable of rendering the protein inactive 
(Rubio-Cabezas et al., 2011).  In another study, a homozygous nonsense mutation at amino acid 
123 was identified in NGN3 and associated with neonatal diabetes (Pinney et al., 2011).  These 
results suggest NGN3 plays a role in human islet cell specification. 
Ectopic and overexpression studies have further elucidated the function of Ngn3 during mouse 
development.  Mice with Pdx1 promoter-driven expression of Ngn3 show decreased pancreatic 
bud size with increased endocrine cell numbers as marked by glucagon expression and the 
endocrine factor Isl1 (Apelqvist et al., 1999).  Another study analyzed the effect of ectopic Ngn3 
expression driven by the Pdx1 promoter, and reported similar findings (Schwitzgebel et al., 
2000).  There was increased and early differentiation of endocrine cells in these mutant mice, 
which were predominantly glucagon-producing alpha cells (Schwitzgebel et al., 2000).  Ectopic 
Ngn3 expression was also performed in chick embryos via in ovo electroporation.  This was 
sufficient to drive endocrine cell differentiation in regions ectopic to normal pancreas 
development, including the esophagus.  These endocrine cells expressed either glucagon or 






pancreatic polypeptide-expressing cells were not found (Grapin-Botton et al., 2001).  This is in 
contrast to the ectopic expression of Pdx1, which was insufficient for endocrine cell fate 
induction (Grapin-Botton et al., 2001).  These studies elucidated a functional role of Ngn3 for the 
induction of endocrine cell fate, and revealed the requirement for additional factors to 
differentiate non-alpha cell endocrine identities. 
Recently, Ngn3
+
 cell potency has been of particular interest because of the current optimization 
of in vitro beta cell differentiation efficiency.  While these cells have traditionally been thought 
to be multipotent and capable of giving rise to any of the endocrine cell types, recent studies 
have suggested restriction in their potential (Desgraz and Herrera, 2009; Johansson et al., 2007).  
The results of these studies are surprising and relevant to in vitro differentiation protocols for 
diabetic replacement therapies.  If the Ngn3
+
 cells generated during these protocols are pre-
biased in their endocrine fate, then it will be of utmost importance to characterize this 
heterogeneity and identify discriminating markers to improve beta cell generation efficiency. 
The first of these recent studies identified temporal windows of endocrine fate competence 
throughout developmental progression.  Johansson et al. (2007) employed a Ngn3 “addback” 
approach to enable temporal control of endocrine differentiation.  Ngn3 expression was induced 
at numerous developmental time points using a Pdx1 promoter-driven Ngn3-ER allele in a Ngn3
-
/-
 mouse background.  The type of endocrine cell specified at each time point was characterized.  
Surprisingly, strict windows of endocrine cell competence were found throughout pancreas 
development.  The first cells capable of forming were alpha cells, beginning at E8.7.  This is 






alpha cells (Apelqvist et al., 1999; Grapin-Botton et al., 2001; Schwitzgebel et al., 2000).  
Competence to form beta cells and PP cells was acquired between E10.5 and E12.5.  Finally, 
delta cells are able to form after E14.5 (Johansson et al., 2007).  This data suggests that 
progenitor cells acquire competence for different endocrine fates during distinct temporal 
windows of development.  These results are also consist with other studies showing that Ngn3
+
 
endocrine progenitor cell competence is cell autonomous and not due to instructive cues from the 
surrounding mesenchyme during development (Gittes, 2009).   
To directly trace the fate of single Ngn3
+
 cells, Desgraz and Herrera (2009) used mosaic analyses 
with double markers (MADM) to allow in vivo clonal analysis of endocrine progenitors.  They 
found that single Ngn3
+
 cells gave rise to single hormone-producing endocrine cells.  This is 
consistent with earlier studies suggesting Ngn3
+
 cells are quiescent (Gu et al., 2002; Jensen et al., 
2000a; Miyatsuka et al., 2011).  Adult analysis showed small clusters of labelled cells that all 
produced the same hormone, indicating minimal postnatal proliferation.  Desgraz and Herrera 
proposed a model in which Ngn3
+
 cells are unipotent, suggesting the entire Ngn3
+
 endocrine 
progenitor population is comprised of multiple unipotent subpopulations (Desgraz and Herrera, 
2009). 
These studies suggest temporal and cell autonomous mechanisms of endocrine fate regulation; 
however, the precise mechanism of this process is still poorly understood.  Elucidating these 








While Pdx1 and Ngn3 mark the pancreatic and endocrine progenitor populations, respectively, 
these are just two examples of many transcription factors that play a role in endocrine cell 
specification (Fig. 1-2).  Transgenic mice with mutations in single transcription factors have 
been characterized and their requirement for beta cell specification is well-established.  Many of 
these factors are also thought to regulate each other in a hierarchical manner.  Rfx6, NeuroD1, 
and Nkx2.2 are three such factors known to be required for beta cell specification. 
Rfx6 is a winged helix transcription factor recently identified and implicated in beta cell 
development.  Rfx6 is transiently expressed in the Pdx1
+
 pancreatic progenitors from E9.0 to 
E10.5.  After this time, Rfx6 is expressed in the Ngn3
+
 endocrine progenitors and in alpha, beta, 
delta, and PP endocrine lineages (Soyer et al., 2010).  Soyer et al. (2010) suggested that Rfx6 
functions downstream of Ngn3, since its expression is lost in Ngn3
-/-
 animals.  In addition, they 
suggested that Rfx6 is either upstream or independent of NeuroD1 since Rfx6 gene expression is 
unchanged in NeuroD1
-/-
 animals (see below) (Naya et al., 1997; Soyer et al., 2010). 
Rfx6 morpholino experiments in zebrafish showed disrupted endocrine cell specification:  loss of 
alpha and epsilon cells, decreased delta cells, and a modest decrease in beta cells (Pearl et al., 
2011; Soyer et al., 2010).  Another study characterized Rfx6
-/-
 mice, which display loss of all 
endocrine cell types, except PP cells (Smith et al., 2010).  The expression of Ngn3 and Nkx2.2 
were unchanged in these mice, suggesting Rfx6 functions downstream of those factors.  






2010).  These results reveal a functional role for Rfx6 in endocrine fate determination in both 
zebrafish and mice. 
Mutations in human RFX6 have been identified in cases of neonatal diabetes.  Smith et al. (2010) 
detected missense, splicing, and frameshift mutations in five out of six autosomal recessive cases 
of neonatal diabetes (Smith et al., 2010).  Additional case studies of neonatal diabetes have 
identified missense mutations in RFX6 which were predicted to disrupt splicing or RFX6 
function (Chandra et al., 2014; Concepcion et al., 2014).  As observed with PDX1 and NGN3, 
RFX6 also appears to function in a similar manner across species. 
NeuroD1 
NeuroD1 (aka BETA2) is a basic helix-loop-helix (bHLH) transcription factor.  This factor was 
first isolated based on its binding to an E-box sequence within the insulin gene promoter, and 
NeuroD1 was found to activate insulin expression (Naya et al., 1995).  NeuroD1 expression can 
be detected in alpha, beta, and delta cells (Naya et al., 1997; Naya et al., 1995).  Co-expression 
analysis of NeuroD1 and Ngn3 in the developing pancreas reveals that 40% of NeuroD1
+
 cells 
co-express Ngn3 mRNA at E9.0.  This co-expression decreases in frequency at E14.5 and E16.5 
but can still be detected (Huang et al., 2000).  The specific expression pattern of NeuroD1 and its 
regulation of insulin implicates it in beta cell development. 
To explore the function of NeuroD1 in beta cell specification, NeuroD1
-/-
 mice have been 
analyzed.  NeuroD1
-/-
 mice display severe hyperglycemia at birth and die perinatally (Naya et al., 
1997).  These mice show a large decrease in beta cell numbers by approximately E17.5 and also 






severity of this phenotype may be dependent on mouse genetic background (Huang et al., 2002).  
This implicates NeuroD1 as an essential regulator of beta cell differentiation during late pancreas 
development and is necessary to establish proper beta cell numbers.  NEUROD1 frameshift 
mutations have also been identified in humans presenting with permanent neonatal diabetes 
(Rubio-Cabezas et al., 2010), and NEUROD1 mutations have been associated with an increased 
risk for the development of diabetes (Malecki et al., 1999), suggesting conservation of NeuroD1 
function. 
NeuroD1 is known to function as a transcriptional activator.  In addition to its role in regulating 
insulin gene expression, NeuroD1 regulates an important beta cell maturation factor, MafA 
(Artner et al., 2010; Wang et al., 2006; Zhang et al., 2005).  In an in vitro beta cell line, NeuroD1 
binds an enhancer sequence of MafA, which is highly conserved in humans.  Mutation of the 
NeuroD1 binding motif results in decreased activation, suggesting that NeuroD1 directly 
activates MafA in beta cells (Raum et al., 2010). 
While NeuroD1 transcriptionally regulates numerous downstream factors essential for beta cell 
formation and function, many transcription factors lie upstream of NeuroD1.  One direct 
regulator of NeuroD1 is Ngn3.  Ngn3 has been found to bind and regulate NeuroD1 directly at its 
promoter (Anderson et al., 2009a; Huang et al., 2000).  Additionally, overexpression of Ngn3 in 
Xenopus and in an in vitro beta cell line also results in NeuroD1 induction (Huang et al., 2000).  
Since Ngn3 expression is also not changed in NeuroD1
-/-
 mice, this supports a hierarchical model 







Nkx2.2 is a homeodomain transcription factor expressed in the central nervous system (CNS), 
intestine, and pancreas (Arnes et al., 2012b; Price et al., 1992; Sussel et al., 1998).  Nkx2.2 was 
first identified in the developing CNS, in the hindbrain and forebrain (Price et al., 1992).  It is 
involved in the differentiation of V3 interneurons (Briscoe et al., 2000; Ericson et al., 1997), 
oligodendrocytes (Qi et al., 2001; Zhou et al., 2001), and serotonergic neurons (Briscoe et al., 
1999; Pattyn et al., 2003).  In the intestine, Nkx2.2 is expressed in many of the enteroendocrine 
cells and a fraction of the Ngn3
+
 endocrine progenitor population (Desai et al., 2008; Wang et 
al., 2009).  Nkx2.2 is required in the intestine for proper enteroendocrine cell specification 
(Desai et al., 2008; Wang et al., 2009).  Similarly, in the pancreas, Nkx2.2 is necessary for the 
differentiation of endocrine cell lineages (Sussel et al., 1998). 
Nkx2.2 is expressed early in pancreas development, coincident with Pdx1, in the emerging dorsal 
bud at E8.75 and the ventral bud at E9.5 (Jorgensen et al., 2007; Sussel et al., 1998).  Its 
expression is maintained throughout pancreas development, during endocrine specification, and 
later in the alpha, beta, PP, and G cells of the pancreas (Suissa et al., 2013; Sussel et al., 1998).  
Nkx2.2 expression precedes that of Ngn3 (Schwitzgebel et al., 2000). 
Nkx2.2 is essential for proper endocrine cell specification and for beta cell formation.  Nkx2.2
-/-
 
mice display a complete loss of beta cells, a decrease in alpha, G, and PP cells, and a striking 
increase in epsilon cells (Prado et al., 2004; Suissa et al., 2013; Sussel et al., 1998).  These mice 
are hyperglycemic and die shortly after birth (Sussel et al., 1998).  This phenotype demonstrates 






and prolonged expression of Nkx2.2 during pancreas development, the timing of Nkx2.2 
influence on endocrine specification is not known. 
The precise mechanism of Nkx2.2 action is currently under investigation.  The Nkx2.2 protein 
contains three conserved domains:  a homeodomain, tinman (TN) domain, and NK2 specific 
(SD) domain (Fig. 1-3A).  The homeodomain is responsible for the DNA-binding activity of 
Nkx2.2 (Kim and Nirenberg, 1989; Tsao et al., 1995; Watada et al., 2000), which recognizes the 
motif T(t/c)AAGT(a/g)(c/g)TT and a second core motif GAGT (Hill et al., 2011; Watada et al., 
2000).  In addition, recent evidence has suggested that Nkx2.2 frequently binds to distal 
enhancers for transcriptional regulation (Dominguez Gutiérrez et al., 2016).  The TN domain is 
essential for proper beta cell specification and mediates interaction with Groucho 3 (Grg3), a co-
repressor (Doyle et al., 2007; Papizan et al., 2011).  Lastly, the SD domain is a feature unique to 
the NK2 family of proteins.  Watada et al. (2000) found that the SD domain does not contribute 
to DNA binding, and that it may be involved in masking strong activation driven by the C-
terminus (Watada et al., 2000).  While these studies were confined to in vitro cell lines, our lab 
has investigated the role of the Nkx2.2 SD domain in vivo during the development of the 
pancreas and CNS (Levine et al., in preparation). 
To influence endocrine cell fate, Nkx2.2 functions both as a transcriptional activator and a 
repressor.  Mice containing an Nkx2.2-dominant-repressor fusion protein (Nkx2.2hd-EnR) show 
rescued beta cell differentiation in an Nkx2.2
-/-
 background.  However, expression of the mature 






2007).  This suggests Nkx2.2 repressor activity is sufficient to specify the beta cell lineage, 
though Nkx2.2 activating functions are necessary to establish a fully functional beta cell fate. 
NKX2-2 has also been implicated in human pancreatic development.  Nonsense or frameshift 
mutations in NKX2-2 were identified in three patients with defects in insulin secretion and 
hyperglycemia early in life (Flanagan et al., 2014).   
Given the early expression of Nkx2.2 and its importance during pancreatic beta cell 
specification, both in mice and humans, this thesis work focuses on elucidating the timing and 
mechanism of Nkx2.2 action.  
Rfx6, NeuroD1, and Nkx2.2 mutant mice have been thoroughly characterized, and their essential 
function in beta cell specification is well-established.  These beta cell developmental factors are 
thought to function in a transcriptional hierarchy.  Nkx2.2 appears to function upstream of Rfx6 
and NeuroD1 since expression of each factor is reduced in Nkx2.2
-/-
 mice (Chao et al., 2007) 




 mice (Chao et al., 
2007; Smith et al., 2010).  Furthermore, Ngn3 and Nkx2.2 have been shown to cooperate for 
NeuroD1 activation through direct regulation of the NeuroD1 promoter, suggesting both Nkx2.2 
and Ngn3 function upstream of NeuroD1 (Anderson et al., 2009a).  Ngn3 is also believed to 
function upstream of NeuroD1 since Ngn3
+
 cell numbers are not changed in NeuroD1
-/-
 mice at 
E18.5 (Schwitzgebel et al., 2000).  Nkx2.2 has been shown to affect Ngn3, with Nkx2.2
-/-
 mice 
showing reduced Ngn3 expression.  Although Ngn3
+
 cell numbers are unaffected in Nkx2.2
-/-
 
mice (at E15.5 or E18.5), reduced levels of Ngn3 at an individual cell level may influence 











compound mutant mice show complete beta cell loss, consistent with the Nkx2.2
-/-
 phenotype.  





mice compared to Nkx2.2
-/-
 mice (Chao et al., 2007).  This study revealed an epistatic 
relationship between Nkx2.2 and NeuroD1 in endocrine specification.  Together, these findings 
suggest that Nkx2.2 is upstream of Rfx6 and NeuroD1, and that these factors may interact 
directly or indirectly to regulate endocrine cell fate (Fig. 1-3B).  Spatiotemporal analysis of such 
interactions has yet to be investigated. 
Human Pancreas Development 
As previously described, sequencing of patients with neonatal diabetes has provided insight into 
the conservation of transcription factor function between mice and humans.  Additional studies 
have explored transcription factor expression patterns during human pancreas development. 
Similar to murine pancreas development, PDX1 is expressed in humans in the newly emerging 
pancreatic bud at 26 days post conception (dpc) (Piper et al., 2004).  Additionally, it’s been 
shown that between gestational week 7 (G7w, gestation 7 week) to G21w, PDX1 is expressed in 
the proliferating epithelial progenitor cells (Jeon et al., 2009).   
NGN3 is expressed beginning at G9w and is highly expressed until G17w (Jeon et al., 2009).  
During this time, islets begin to form at approximately G11w (Pan and Wright, 2011), with large 
increases in INSULIN, GLUCAGON, and SOMATOSTATIN occurring between G7w and 
G18w (Jeon et al., 2009; Polak et al., 2000).  Early endocrine cells have been found to co-express 






(Polak et al., 2000; Sarkar et al., 2008).  This developmental time point is similar to the second 
wave of endocrine cell differentiation observed in mice between E13.5 and E18.5, with the peak 
of Ngn3 expression at E15.5 (Pan and Wright, 2011; Schwitzgebel et al., 2000). This expression 
pattern, with NGN3 expression tightly linked to endocrine cell differentiation, suggests a similar 
mechanism of endocrine fate induction between species. 
NKX2-2 expression has been observed from G7w to G23w; however, its expression earlier than 
G7w has yet to be identified (Jeon et al., 2009; Sarkar et al., 2008).  Additionally, NEUROD1 
expression is first observed after NKX2-2, at G15w (Jeon et al., 2009).   
One major difference between adult murine and human pancreas lies in the structure of the islet 
of Langerhans.  In adult mice, beta cells are clustered predominantly in the center of the islet, 
with other endocrine cell types scattered in the periphery (Levetan and Pierce, 2013).  In 
contrast, adult human islets are structured with all endocrine cell types intermingled amongst 
each other, with no apparent organization resembling the mouse (Levetan and Pierce, 2013).  
Interestingly, recent studies have discovered human islets show variability in structure, with 
smaller islets showing arrangements similar to murine organization and larger islets containing 
intermingled cell types (Bonner-Weir et al., 2015).  In addition, human endocrine cells may go 
through a temporary clustered state during development where INSULIN
+
 cells are located in the 
center of the islet and GLUCAGON
+
 cells are in the periphery at G14w (Jeon et al., 2009).  
These findings provide additional evidence of shared mechanisms of endocrine cell specification 






Maintenance of Beta Cell Identity and Function 
While cell fate was considered to be determined developmentally, recent studies have 
unexpectedly identified residual plasticity in terminally differentiated cells, including pancreatic 
beta cells. 
Under diabetic conditions, pancreatic beta cells can undergo numerous transformations including 
loss of function, loss of identity, dedifferentiation, and/or reprogramming.  These 
transformations have been noted in diabetic mouse models, including:  beta cell-specific FoxO1 
ablation (FoxO1
∆beta
), GIRKO, and db/db mice.  Lineage-tracing in FoxO1
∆beta
 mice shows loss 
of beta cell maturation markers and expression of developmental factors including Ngn3, Oct4, 
Nanog, and L-Myc.  Additionally, these cells can go on to express glucagon.  This process of 
“dedifferentiation” was also observed in GIRKO and db/db diabetic mouse models; beta cells 
showed loss of mature factors, such as MafA, and an increase in Ngn3 (Talchai et al., 2012).  
Additional studies have demonstrated the loss of mature beta cell factors under stressful 
conditions similar to the conditions induced during diabetes (Guo et al., 2013).  These results 
demonstrate not only the plasticity of beta cells, but also the relevance of this plasticity during 
diabetes disease progression. 
Beta cell transdifferentiation can also occur when beta cells express other pancreatic hormones.  
Typically this process does not necessarily involve dedifferentiation, which is characterized by 
the expression of progenitor factors, such as Ngn3.  The process of transdifferentiation has been 
suggested to occur in cases of both T1D and T2D.  In non-obese diabetic (NOD) mice, a mouse 






somatostatin can be found, potentially indicative of transdifferentiation (Piran et al., 2014).  In 









expressing cells can also be found (White et al., 2013; Yoneda et al., 2013).  These 
polyhormonal cells were sometimes found to co-express NGN3 (Yoneda et al., 2013).  These 
mechanisms of transdifferentiation, dedifferentiation and loss of beta cell identity appear to be 
integral components of diabetes progression; therefore, analysis of the mechanisms involved 
could prove useful for the development of novel disease therapies. 
Transcription factors important for beta cell specification during embryonic development have 
also been implicated in the maintenance of beta cell fate within adult mice.  While Pdx1 is 
expressed in the pancreatic progenitor population, it is also expressed in murine and human beta 
cells (Jeon et al., 2009; Ohlsson et al., 1993; Piper et al., 2004).  Beta cell specific deletion of 
Pdx1 with rat insulin promoter (RIP)-Cre; Pdx1
flox/flox
 mice reveals an important role for Pdx1 in 
maintaining beta cell identity and function.  These mice show decreased insulin expression, 




 co-positive cells.  There is also 
decreased expression of the glucose transporter, Glut2, which is essential for proper glucose-
stimulated insulin secretion (GSIS) (Guillam et al., 1997).  As a result of these defects, RIP-Cre; 
Pdx1
flox/flox
 mice develop diabetes, demonstrating a requirement for Pdx1 within the beta cell to 
maintain its proper function in glycemic control (Ahlgren et al., 1998).  Another study induced 
Pdx1 ablation at 1 month of age in RIP-CreER; Pdx1
flox/flox
 mice.  These mice displayed loss of 
beta cell identity, with decreases in insulin and Glut2 expression.  In addition, lineage-tracing 
revealed beta to alpha cell conversion, with lineage-labeled cells expressing glucagon and other 






Rfx6 is also necessary within the adult beta cell to maintain function.  Piccand et al. (2014) 
ablated Rfx6 at 8 to 10 weeks of age with tamoxifen administration of Ins1-CreER; Rfx6
flox/flox
 
mice.  These mice displayed hyperglycemia and glucose intolerance, likely resulting from 
defective insulin secretion and decreased expression of genes important for GSIS (Piccand et al., 
2014).  There was also inappropriate activation of genes that are selectively repressed in normal 
islets (Piccand et al., 2014), which are called “disallowed” genes (Pullen et al., 2010; Thorrez et 
al., 2011).  Rfx6 is also expressed and required in human beta cells.  In the EndoC-betaH2 
human beta cell line, RFX6 knockdown results in defective insulin secretion (Chandra et al., 
2014).  These studies highly an important function for Rfx6 in adult beta cells both in mice and 
humans. 
Recently Nkx2.2 has been implicated in maintaining beta cell function and identity.  RIP-Cre; 
Nkx2.2
flox/flox
 and MIP-CreER; Nkx2.2
flox/flox
 mice display glucose intolerance with decreases in 
insulin, Glut2, Pdx1, and other genes important for beta cell function.  These mice also contain 
polyhormonal cells, with frequent co-expression of insulin with glucagon, somatostatin, or 
pancreatic polypeptide found in adult islets.  In addition, knockdown of NKX2-2 in human islets 
resulted in similar effects, revealing species conservation (Dominguez Gutiérrez et al., 2016). 
Lastly, NeuroD1 is required to maintain functional maturity in beta cells.  Beta cell-specific 
ablation of NeuroD1 in RIP-Cre; NeuroD1
flox/flox
 mice results in glucose intolerance resulting 




 co-positive cells was observed 






Interestingly, Pdx1 and MafA expression was unchanged, indicating NeuroD1 is not important 
for maintaining expression of these factors (Gu et al., 2010). 
These studies have revealed essential roles for Pdx1, Rfx6, Nkx2.2, and NeuroD1 in maintaining 
adult beta cell identity.  It is possible that these transcription factors exert their effects through 
cooperative binding at enhancer regions.  Recently, transcription factor ChIP-Seq experiments 
(including PDX1 and NKX2.2) were conducted on isolated human islets and cross referenced to 
histone marks indicative of promoters, active enhancers, and inactive enhancers.  These results 
showed numerous transcription factors, including PDX1 and NKX2.2 binding to enhancers, 
implicating co-regulation of islet genes.  In addition, RFX and bHLH motifs were identified in 
these enhancer regions, suggesting binding of RFX6 and NEUROD1 is also likely.  Moreover, 
T2D risk variants were frequently found at these distal enhancer regions, suggesting functional 
relevance of these sites (Pasquali et al., 2014).  These findings may reflect a common mechanism 




Given the complex regulatory mechanisms associated with the development, differentiation and 
maintenance of beta cells, there are still many outstanding questions regarding islet cell 
specification.  Overall, this thesis work investigates the timing and mechanism of pancreatic beta 
cell specification.  Previous studies have shown that Nkx2.2 is an essential transcription factor 
for beta cell formation and establishing proper ratios of endocrine cell fate (Prado et al., 2004; 






developmental time point, the temporal regulation of beta cell differentiation is investigated.  
Through careful analysis of the endocrine cell lineages and comparison to the Nkx2.2
-/-
 
phenotype, we identified a critical window of development.  In addition, ChIP-Seq datasets for 
Nkx2.2 (Dominguez Gutiérrez et al., 2016), Rfx6 (Piccand et al., 2014), and NeuroD1 (Tennant 
et al., 2013) were cross-referenced, identifying co-occupancy among these beta cell transcription 
factors near endocrine-related genes.  These results are indicative of combinatorial interactions 
and transcription factor cooperation during cell fate specification. 
Furthermore, the mechanism of Nkx2.2 function was assessed using mice with mutations in a 
conserved domain, the Nkx2.2 SD domain.  This thesis work revealed an important function for 
the SD domain in mediating the role of Nkx2.2 in maintaining beta cell function.  In addition, the 
transcriptional profile of endocrine progenitors was assessed, revealing early transcriptional 
regulation of endocrine cell fate. 
These studies have revealed novel processes involved in beta cell specification, in addition to the 
maintenance of beta cell function.  A current area of research for novel diabetic therapies 
involves the differentiation of beta cells in vitro and transplantation of these cells into patients to 
restore glucose homeostasis.  The features of in vivo beta cell development that have been 










Figure 1-1. Endocrine progenitor delamination and migration.  Following Ngn3 expression, 
endocrine progenitor cells delaminate from the pancreatic trunk epithelium.  These cells are 
thought to undergo a process similar to epithelial-mesenchymal transition (EMT).  They migrate 









Figure 1-2. Transcription factors involved in pancreas development. Numerous transcription 










Figure 1-3. Nkx2.2 structure and function. (A) Nkx2.2 contains a tinman (TN) domain, 
homeodomain (HD), and specific domain (SD). (B) Nkx2.2 functions upstream of NeuroD1 and 








SUBMITTED MANUSCRIPT:  NKX2.2 REPRESENTS AN ESSENTIAL 
COMPONENT OF A MODULAR REGULATORY PROGRAM TO 
INDUCE PANCREATIC BETA CELL FATE 
 
Angela Churchill generated all data except for the ChIP-Seq analyses.  The 
Nkx2.2 ChIP-Seq was performed by Giselle Dominguez Gutiérrez (Dominguez 
Gutiérrez et al., 2016; GSE79725). Bioinformatic analysis and Fisher’s Exact Test 
was conducted by Ruth Singer. 
 
Abstract 
Many transcription factors that are essential for islet cell differentiation have been well 
characterized; however, the precise timing and functional hierarchy by which these factors 
regulate beta cell fate induction remains unknown.  To elucidate the spatiotemporal mechanism 
of beta cell differentiation, we ablated Nkx2.2, one of the earliest and most broadly expressed 





mice display defective beta cell differentiation and recapitulate the 
Nkx2.2
KO
 phenotype.  Furthermore, we demonstrate that despite the striking defect in beta cell 
formation, expression of many essential components of the beta cell regulatory network that are 
regulated by Nkx2.2 in pancreatic progenitor cells remain intact in the Nkx2.2
∆endo 
mice. This 
suggests that within the Ngn3 progenitor Nkx2.2 functions as an obligatory component of a 
modular regulatory program to induce beta cell fate, and illustrates the combinatorial, rather than 
hierarchical nature of the beta cell regulatory pathways.  Accordingly, a large proportion of 






modules may reflect a fundamental feature of beta cell fate specification, and will have 
significant implications for the optimization of in vitro beta cell differentiation protocols. 
Introduction 
Pancreatic beta cell specification involves the progressive restriction of progenitor-cell lineage 
potential through the sequential expression of several essential transcription factors.  Pancreatic 
bud initiation is associated with the expression of pancreatic and duodenal homeobox 1 (Pdx1), a 
transcriptional regulator that delineates the multipotent pancreatic progenitor population 
(Jonsson et al., 1994; Offield et al., 1996).  These Pdx1
+
 cells give rise to all cell types of the 
mature pancreas and deletion of Pdx1
+
 leads to pancreatic agenesis (Burlison et al., 2008; Gu et 
al., 2003; Jonsson et al., 1994; Offield et al., 1996).  A subset of cells from the Pdx1
+
 lineage 
subsequently become restricted to the endocrine lineage with the expression of Neurogenin 3 
(Ngn3), which delineates the endocrine progenitor.  Ngn3 is essential for the formation of all six 
pancreatic endocrine cell types:  the insulin-producing beta cells, glucagon-producing alpha 
cells, somatostatin-producing delta cells, pancreatic polypeptide-producing PP cells, gastrin-
producing G cells, and ghrelin-producing epsilon cells (Gradwohl et al., 2000; Gu et al., 2002; 
Heller et al., 2005; Schwitzgebel et al., 2000; Suissa et al., 2013). Mice lacking Ngn3 fail to form 
these endocrine lineages (Gradwohl et al., 2000; Heller et al., 2005; Suissa et al., 2013). 
Although it is well-established that beta cells are derived from the Ngn3 progenitor lineage, there 
is still some uncertainty about when and where the beta cell lineage is specified during pancreas 
development.  Beta cell fate may be influenced early within the Pdx1
+
 pancreatic progenitor to 
specify unipotent populations of Ngn3
+






or it may be occurring within the Ngn3
+
 endocrine progenitor lineage after induction of Ngn3. 
Interestingly, Johansson et al. (2007) demonstrated that pancreatic progenitor cells transition 
through distinct competence windows in response to Ngn3 expression for each endocrine cell 
fate, with beta cell competence being acquired during a strict window of development, between 
E10.5 and E12.5 (Johansson et al., 2007).  Although many of the transcription factors essential 
for beta cell specification have been identified, we still have an incomplete understanding of how 
these factors regulate the timing and mechanism of beta cell fate induction since they are 
expressed both early and throughout pancreas development. For example, Glis3, NeuroD1, 
Nkx2.2 and Rfx6 are all expressed in multipotent pancreatic progenitors and endocrine 
progenitors.  All four of these mouse mutants die shortly after birth due to their severe defects in 
beta cell development (Naya et al., 1997; Prado et al., 2004; Smith et al., 2010; Suissa et al., 
2013; Sussel et al., 1998); however, it is unknown exactly when each of these factors exert their 
functional role in beta cell fate specification. 
To gain a better understanding of both the timing and mechanism of beta cell fate induction we 
chose to focus on the essential islet transcription factor, Nkx2.2.  Beta cell fate specification is 
completely dependent on Nkx2.2; no beta cells are formed in mice carrying a -/- mutation in 
Nkx2.2 (Sussel et al., 1998). Nkx2.2 is co-expressed with Pdx1 throughout the pancreatic 
progenitor domain, but its expression becomes restricted to the Ngn3
+
 endocrine progenitor 
population (Arnes et al., 2012b; Jorgensen et al., 2007; Sussel et al., 1998). Nkx2.2 also appears 
to function at or near the top of the regulatory cascade of transcription factors to specify beta cell 
fate: The expression of Ngn3, Nkx6.1, Rfx6 and NeuroD1 is significantly reduced in Nkx2.2
KO
 






suggesting that Nkx2.2 functions upstream of these factors.  The early expression of Nkx2.2 
within the multipotent progenitor population, upstream of Ngn3 prompted us to determine 





) mice to ablate Nkx2.2 specifically within the Ngn3
+
 
endocrine progenitor lineage.  Although Nkx2.2 is expressed upstream of Ngn3 and regulates 
Ngn3 expression (Anderson et al., 2009a; Sussel et al., 1998), deletion of Nkx2.2 downstream of 
Ngn3 resulted in severe endocrine defects similar to the Nkx2.2
KO
 phenotype.  Notably, Ngn3 
expression in the Nkx2.2
∆endo
 mice was not affected. This finding identifies a critical window for 
Nkx2.2 regulation of beta cell specification within the endocrine progenitor cell downstream of 
Ngn3 activation. Furthermore, unlike the Nkx2.2
KO
 mice, expression of several essential beta 
cell transcription factors, including Rfx6 and NeuroD1, was unaffected. Co-occupancy analysis 
revealed significant overlap between Nkx2.2 direct targets and Rfx6 and NeuroD1 bound genes.  
This indicates that the failure of beta cell formation may not be strictly due to reduction of a 
linear transcriptional regulatory cascade that functions downstream of Nkx2.2 and implicates 
Nkx2.2 as an essential component of a modular beta cell transcription network. 
Results 
Nkx2.2 is efficiently ablated in Nkx2.2
∆endo
 mice 
Nkx2.2 is expressed at the onset of pancreas development throughout the multipotent progenitor 
domain, but subsequently becomes restricted to the Ngn3
+
 endocrine progenitor population 
(Jorgensen et al., 2007).  Furthermore, -/- mutations in Nkx2.2 (Nkx2.2
KO
) lead to reduced Ngn3 
expression (Anderson et al., 2009b). To determine whether Nkx2.2 function downstream of 










R26R-Tomato (hereafter referred to as Nkx2.2
∆endo
) mice were generated to ablate Nkx2.2 
specifically within the endocrine progenitor cells and their descendants (Madisen et al., 2010; 
Mastracci et al., 2013; Schonhoff et al., 2004). Efficient deletion of Nkx2.2 in the Nkx2.2
∆endo
 
mice could be demonstrated by a reduction in Nkx2.2 mRNA expression at E15.5 and E18.5 
(Fig. 2-1A). Residual Nkx2.2 gene expression at E15.5 likely reflects Nkx2.2 expression in 
pancreatic progenitor cells that are still present at this stage of development. Consistent with the 
decrease in Nkx2.2 gene expression, Nkx2.2 protein was almost undetectable in the pancreas at 
E15.5 and postnatal day (P)0 (Fig. 2-1B,C; Supplemental Fig. 2-1A,B). Activation of the R26R-
Tomato allele was also used to monitor accurate Cre activity within the Nkx2.2
∆endo





) cells were found specifically within the endocrine compartment 
(Supplemental Fig. 2-1D,E). 
Deletion of Nkx2.2 from the endocrine progenitor population did not affect Ngn3 expression, nor 
the Ngn3-expressing endocrine progenitor population (Supplemental Table 2-1, Fig. 2-1D,E).  
Furthermore, the expression of Sox9, a progenitor marker that is expressed upstream of Ngn3 
was unaffected and there were no obvious changes in the exocrine lineage, as indicated by 
amylase expression (Supplemental Fig. 2-1C-E).  The area of Tomato expression and 
ChromograninA (ChgA), Isl1, and Pax6 gene expression were also unchanged, suggesting 
endocrine compartment size and pan-endocrine gene expression were unchanged in the absence 








 mice display similar endocrine defects as Nkx2.2
KO
 mice 
Since Nkx2.2 is necessary for the establishment of proper endocrine cell ratios, we assessed the 
status of endocrine cell differentiation in the Nkx2.2
∆endo
 mice during the course of pancreas 
development.  Similar to the Nkx2.2
KO
 mice (Prado et al., 2004; Sussel et al., 1998), Nkx2.2
∆endo
 























cell number at P0 (Fig. 2-2K-L).  Unlike the Nkx2.2
KO
 mice which lack all beta cells, we could 
detect a small number of Ins
+
 cells (Fig. 2-2A-L; Supplemental Fig. 2-2), which is possibly due 
to the efficiency of the Ngn3-Cre allele. Gene expression at E15.5 and E18.5 corresponded to 
changes in endocrine cell numbers.  Insulin (Ins1 and Ins2) and glucagon (Gcg) expression were 
significantly decreased; there was increased ghrelin (Ghrl) expression, and no change in 
somatostatin (Sst) gene expression at E15.5 and E18.5 (Fig. 2-2M).  Gastrin (Gast) gene 
expression was also decreased at E15.5, but became normalized by E18.5 (Fig. 2-2M), likely due 
to the embryo-restricted presence of the G cell population in the pancreas (Suissa et al., 2013). 
Similar to the Nkx2.2
KO
 mice, the Nkx2.2
∆endo
 mice die shortly after birth between P2 and P4 
(Fig. 2-2N).  
Unexpectedly, we observed a significant increase in (pancreatic polypeptide) Ppy expression at 
E15.5 and E18.5 in Nkx2.2
∆endo 
embryos (Fig. 2-2M).  This is in contrast to our previous studies, 
in which we had observed a decrease in Ppy gene expression and PP
+
 cell numbers (Chao et al., 
2007; Prado et al., 2004; Sussel et al., 1998). To confirm the upregulation of Ppy in Nkx2.2
∆endo 
embryos and directly compare Ppy expression in the Nkx2.2
KO










) pancreas (Arnes et al., 2012b).  Surprisingly, in 
this new analysis, Ppy expression was upregulated in the Nkx2.2
KO
 (Fig. 2-2O) and it appears that 




embryos, although to a greater 
magnitude in the Nkx2.2
∆endo 
embryos (Fig. 2-2M,O).  We could also demonstrate that 





 cells at both E15.5 and P0 (Supplemental Fig. 2-3A-F).  Quantification of 
PP
+
 cells normalized to total Tom
+
 cell number also confirmed a > two-fold increase in PP
+
 cells 




 cells could be observed (arrow in 
Supplemental Fig. 2-3D), there was no significant difference between Nkx2.2
∆endo 
mice and 
controls (Supplemental Fig. 2-3G).  The surprising observation that Ppy is upregulated in the 
Nkx2.2
KO
 mice may be due to the availability of more specific Ppy detection reagents, or could 





 mice share important gene expression changes  
It was somewhat unexpected that the restricted deletion of Nkx2.2 in the Ngn3 progenitor cells 
resulted in a phenotype that was remarkably similar to the Nkx2.2
KO
 mice, which lacked Nkx2.2 





 mice during the peak of endocrine cell differentiation, we 





embryos, and their respective littermate controls.  Consistent with their similar phenotypes, there 
was significant overlap (p-value < 2.2e-16, Fig. 2-3A) between the differentially expressed genes 
(adjusted p-value < 0.05), including genes encoding pancreatic hormones (Fig. 2-3B) and 






Supplemental Table 2-1). Furthermore, several transcription factors expressed in endocrine 
progenitors and involved in beta cell specification, such as Nkx6.1, Pax4, and Pdx1, that were 
unchanged Nkx2.2
KO
 embryos were also not affected at E15.5 in Nkx2.2
∆endo
 pancreas 
(Supplemental Fig. 2-4; Supplemental Table 2-1). 
Key regulators Ngn3, NeuroD1, and Rfx6 are retained in Nkx2.2
∆endo
 mice. 
Notably, in sharp contrast to the Nkx2.2
KO
 mice, which have reduced Ngn3, NeuroD1, and Rfx6 
(Anderson et al., 2009a; Chao et al., 2007), expression of Ngn3, NeuroD1, and Rfx6 were 
unaffected in the Nkx2.2
∆endo 
mice (Fig. 2-3E).  We performed qRT-PCR analysis to confirm the 
maintenance of Ngn3, NeuroD1, and Rfx6 gene expression in E15.5 and E18.5 Nkx2.2
∆endo 
mice 
(Fig. 2-3F). Ngn3 mRNA appeared to be increased at E18.5 in the Nkx2.2
∆endo 
mice (Fig. 2-3F); 
however, immunostaining shows no increase in Ngn3
+
 cells at P0 (Fig. 2-3G,H).  These results 
suggest that although Nkx2.2 regulates Ngn3, NeuroD1, and Rfx6 expression within the 
pancreatic progenitor population, regulation of Ngn3, NeuroD1, and Rfx6 expression within the 
endocrine progenitor cells becomes independent of Nkx2.2. Furthermore, this suggests that 
reduction in Ngn3, NeuroD1, and Rfx6 expression in the Nkx2.2
KO
 mice is not a necessary step 
in the disruption of islet lineage specification.  
Nkx2.2 direct targets are co-bound by Rfx6 and/or NeuroD1 
The finding that beta cell specification was disrupted, even though Ngn3, NeuroD1 and Rfx6 
expression remained intact, could indicate that Nkx2.2 functions as an obligate co-factor for 
these proteins in the regulation of beta cell specification. This is supported by our previous 
observation that Nkx2.2 cooperated with Ngn3 to regulate the expression of NeuroD1 (Anderson 






Nkx2.2 within the known beta cell specification regulatory pathways, we assessed whether 
Nkx2.2 co-regulated the beta cell program with Rfx6 and NeuroD1.  Nkx2.2 bound and 
regulated genes were identified by cross-referencing the differentially expressed genes in the 
Nkx2.2
∆endo 
RNA-Seq (adjusted p-value < 0.05, Fig. 2-3) with an Nkx2.2 ChIP-Seq performed 
on the Min6 beta cell line (Dominguez Gutiérrez et al., 2016; GSE79725).  These direct targets 
were compared with an Rfx6 ChIP-Seq performed in Min6 cells (Piccand et al., 2014; 
GSE62844), and a NeuroD1 ChIP-Seq from adult murine islets (Tennant et al., 2013; 
GSE30298).  Notably, there was significant overlap of Rfx6 binding at Nkx2.2 target genes (p-
value < 2.2e-16, Fig. 2-4A).  Gene ontology (GO) analysis also revealed a significant 
representation of genes related to hormone secretion (Fig. 2-4B).  Analysis of NeuroD1 bound 
genes revealed similar overlap with Nkx2.2 targets (p-value < 2.2e-16, Fig. 2-4C), and GO 
analysis identified significant representation of insulin secretion genes (Fig. 2-4D).  Closer 
inspection of the Nkx2.2, Rfx6, and NeuroD1 ChIP-Seq data revealed numerous combinations of 
co-occupancy at pancreas-related genes.  For example, all three transcription factors show 
overlapping binding peaks at the Mlxipl locus (Fig. 2-4E).  At a region upstream of MafA, only 
Nkx2.2 and NeuroD1 are present (Fig. 2-4F); whereas Nkx2.2 and Rfx6 co-bind at the Gast 
locus (Fig. 2-4G).  In addition, Nkx2.2, Rfx6, and NeuroD1 all bind near G6pc2; however, these 
peaks are present at distinct loci surrounding the gene (Fig. 2-4H).  These co-bound targets, 
Mlxipl, MafA, Gast, and G6pc2, have significantly decreased expression at E15.5 in the 
Nkx2.2
∆endo 
pancreas (Fig. 2-4I), indicating Nkx2.2 activity is necessary for their activation.  






regulation of the islet cell program, it is their cooperative function that is required for the 
appropriate activation of a number of essential beta cell genes. 
Discussion 
The spatiotemporal progression of beta cell specification is not well understood.  While many 
transcription factors that are essential for this process are well-characterized, their extended 
expression during development has made it challenging to identify the timing of their function.  
Nkx2.2 is expressed within the Pdx1
+
 pancreatic progenitor population and its expression is 
maintained throughout development, gradually becoming restricted to the endocrine cell lineages 
(Arnes et al., 2012b; Jorgensen et al., 2007; Sussel et al., 1998).  Global deletion of Nkx2.2 
causes the reduction of many essential regulatory factors, including Ngn3, NeuroD1 and Rfx6 
(Anderson et al., 2009a; Chao et al., 2007) (Supplemental Table 2-1).  The fact that these mice 
failed to form beta cells and some of the other islet cell types provided a strong argument for 
positioning Nkx2.2 at the top of the hierarchy for regulation of beta cell specification. In this 
study, we ablated Nkx2.2 specifically within the endocrine progenitor lineage to determine 
whether Nkx2.2 also functions downstream of Ngn3 in regulating islet cell specification.  
Surprisingly, we found similar endocrine changes in Nkx2.2
∆endo
 mice compared to Nkx2.2
KO
 
mice, including the failure to form beta cells (Sussel et al., 1998).  However, unlike the 
Nkx2.2
KO
 mice, expression of the essential beta cell transcription factors Ngn3, Rfx6, and 
NeuroD1 were unaffected, suggesting that although Nkx2.2 regulates these factors in the 
pancreatic progenitor population, reduction of Ngn3, NeuroD1 and Rfx6 expression is not an 






NeuroD1 and Rfx6 are essential for specifying the beta cell program, Nkx2.2 activity must be 
preserved to facilitate the functional integrity of these pathways (Fig. 2-5).  Furthermore, co-
occupancy analysis revealed significant overlap of Nkx2.2 direct targets with Rfx6 and NeuroD1 
binding, suggesting cooperative transcriptional regulation of these factors. 
Although it was unexpected that deletion of Nkx2.2 from the Ngn3
+
 cell was sufficient to 
recapitulate the Nkx2.2
KO
 phenotype, it is consistent with a recent study showing that Ngn3-Cre; 
Rfx6
flox/flox
 mice display beta cell loss similar to the Rfx6
-/-
 mice (Piccand et al., 2014).  
Similarly, Nkx6.1 functions downstream of Ngn3, with Ngn3-Cre; Nkx6.1
flox/flox
 mice displaying 
defective beta cell differentiation (Schaffer et al., 2013).  These studies are providing increasing 
evidence that the endocrine progenitor cell, downstream of Ngn3 induction, is the primary site of 
islet cell specification. However, it is still possible that preprogramming of this population does 
occur, but that the respective programs can be over-written once the cell has formed.  The 
importance of Nkx2.2 function downstream of Ngn3 expression is also consistent with the timing 
of NKX2.2 in human islets; unlike mice, NKX2.2 is only first detected after the appearance of 
NGN3 progenitors (Jennings et al., 2013).  However, while Nkx2.2 function within the mouse 
Pdx1
+
 pancreatic progenitor was not sufficient to allow beta cell formation, further studies would 
be required to determine whether Nkx2.2 has additional functions at this earlier stage of pancreas 
development. 
We were surprised to observe an increase in the PP population of Nkx2.2
∆endo
 mice.  Since re-
evaluation of Ppy expression in the Nkx2.2
KO
 mice revealed a similar phenotype, the increase in 






cells.  It is possible that the different PP phenotype in our earlier studies could be explained by 
the availability of more specific reagents.  In the past, cross-reactivity between PP, peptide YY 
(Pyy), and neuropeptide Y (Npy) antibodies has been observed (Teitelman et al., 1993; Upchurch 
et al., 1994) and the loss of Pyy or Npy expression in the Nkx2.2
KO
 mice could explain the 
apparent reduction in PP expression.  We no longer have access to the anti-PP antibodies used in 
our previous studies, but we can demonstrate that the PP antibodies used in this analysis do not 
cross react with Pyy and Npy (Supplemental Fig. 2-5A-C, data not shown).  It is also possible 
that the discrepant PP phenotype is due to different strain backgrounds, which were changed 
from a Swiss Black (Taconic) background in the previous analyses to a C57Bl6/J background in 
this study. The upregulation of PP is also interesting since it parallels the increase we observed 
with epsilon cells.  Consistent with the observation that a subset of the PP population is derived 




 cells can be infrequently 
found in Nkx2.2
∆endo 
mice at P0 (Supplemental Fig. 2-5D-E). 
Beta cell specification involves the function of numerous transcription factors, some of which are 
expressed early and throughout pancreas development.  Our results identify a critical window for 
Nkx2.2-mediated regulation of islet cell specification within the Ngn3 lineage following 
induction of Ngn3.  Furthermore, although Nkx2.2 appears to function near the top of the islet 
transcriptional hierarchy, it appears that maintained Nkx2.2 activity is also a necessary 
component of the regulatory networks functioning downstream of Ngn3 to induce beta cell 
specification. Our discovery that different combinations of transcription factors bind and regulate 
important genes in the beta cell pathways raises important questions about the complex nature of 






maturation and function.  Furthermore, while previous research has focused on the initial 
expression of beta cell factors, future studies may benefit by ensuring the prolonged and 
combinatorial expression of these factors to recapitulate in vivo development and allow 
cooperative induction of target genes. 
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Materials and Methods 
Animal maintenance  
Mice were maintained on a C57BL/6J background (The Jackson Laboratory).  Ngn3-Cre, 
Nkx2.2
flox/flox or flox/LacZ
, and R26R-Tomato (B6.Cg-Gt(ROSA)26-Sor
tm14(CAG-tdTomato)Hze
/J) mice were 
genotyped as previously published (Arnes et al., 2012b; Madisen et al., 2010; Mastracci et al., 
2013; Schonhoff et al., 2004).  Nkx2.2
LacZ/LacZ
 mice were genotyped as previously published 




 mice are referred to as Nkx2.2
KO
 mice 






accordance with a Columbia University Institutional Animal Care and Use Committee approved 
protocol (AAAG3206). 
Immunohistochemistry 
Fixation:  Samples were fixed in 4% paraformaldehyde (PFA).  E15.5 embryos were fixed for 3 
hours (h) at 4°C, and P0 neonates were fixed overnight at 4°C.  Samples were washed in 
phosphate-buffered saline (PBS), and then transferred to 30% sucrose/PBS overnight at 4°C.  
Samples were embedded and frozen in optimum cutting temperature (O.C.T.) and stored at -
80°C.  8 µm sections were taken and stored at -80°C. 
Staining:  Sections were washed in PBS and 0.1% Triton/PBS (PBST) and blocked in 2% 
donkey serum (DS)/PBST for 30 minutes (min) at room temperature (RT).  Primary antibody 
was diluted in 2% DS/PBST and incubated on sections overnight at 4°C.  Sections were washed 
in PBS and PBST and incubated 2-3 h at RT with secondary antibody (Jackson Immuno 
Research) diluted in 2% DS/PBST at 1:500.  Sections were washed in PBS and PBST and 
incubated with DAPI (Invitrogen TD21490) diluted in PBS at 1:1000 for 15 min at RT.  Sections 
were washed in PBS and mounted with fluorescent mounting medium (DAKO S3023). 
Primary antibodies:  guinea pig α-Insulin (DAKO, 1:500), rabbit α-Nkx2.2 (Sigma, 1:400), goat 
α-Ghrelin (Santa Cruz, 1:500), rabbit α-Glucagon (DAKO, 1:800), rabbit α-Pancreatic 
Polypeptide (Zymed/Invitrogen, 1:200), guinea pig α-Pdx1 (Beta cell biology consortium, 
1:400), rabbit α-Amylase (Sigma, 1:500), rabbit α-Somatostatin (Phoenix Pharmaceuticals, 







Microscopy:  Images were taken using a Zeiss Confocal LSM 710 microscope and processed 
with Zen, ImageJ, and Adobe Photoshop software. 







cell quantification throughout the entire pancreas.  Tiled 
images were taken at 20x objective with a Leica fluorescent microscope (DM5500/MZ16F) and 
processed with LAF software.  Cells were counted using ImageJ software and normalized to total 
number of Tomato
+ 
cells.  All values are expressed as mean ± SEM.  Statistical analysis was 
performed using two-tailed student’s unpaired t-test.  Significance was achieved with p-value < 
0.05. 
RNA analysis 
RNA extraction:  Whole pancreata were dissected in PBS and transferred to RNAlater (Ambion 
AM7021).  Pancreata were incubated at 4°C overnight and stored at -20°C until RNA extraction.  
Pancreata were homogenized and total RNA was isolated following the Qiagen RNeasy Mini kit. 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis:  A 
normalized starting quantity of RNA (200ng-1µg) isolated from whole pancreas and random 
hexamers were used to synthesize cDNA following the SuperScript III reverse transcriptase 
protocol (Invitrogen 18080-044).  qRT-PCR was performed using 200ng cDNA and master mix 
(Eurogentec) and analyzed using the BioRad CFX96 Real-Time System.  Genes were 
normalized to CyclophilinB (probe 5’: tggtacggaaggtggag, forward primer 5’: 
gcaaagttctagagggcatgga, reverse primer 5’: cccggctgtctgtcttggt) and to littermate controls.  An n 






performed using two-tailed student’s unpaired t-test.  Significance was achieved with p-value < 
0.05. 
Applied Biosystems TaqMan AODs:  Insulin1 (Mm01950294_s1), Insulin2 (Mm00731595_gH), 
Glucagon (Mm00801712_m1), Pancreatic polypeptide (Mm00435889_m1), Ghrelin 
(Mm00445450_m1), Somatostatin (Mm00436671_m1), Gastrin (Mm00439059_g1), 
ChromograninA (Mm00514341_m1), Arx (Mm00545903_m1), Pdx1 (Mm00435565_m1), 
Peptide YY (mm00520716), Neuropeptide Y (Mm03048253_m1), Etv1 (Mm00514804_m1), 
Pax6 (Mm00443081_m1), Isl1 (Mm00517585_m1), Sox9 (Mm00448840_m1), Pax4 
(Mm01159036_m1), Glucokinase (Mm00439129_m1), Glut2 (Mm00446229_m1). 
Applied Biosystems Primer/TaqMan Probe sets:  Nkx2.2 (probe 5’: ccattgactctgccccatcgctct, 
forward primer 5’: cctccccgagtggcagat, reverse primer 5’: gagttctatcctctccaaaagttcaaa), 
Neurogenin3 (probe 5’: cctgcgcttcgcccacaact, forward primer 5’: gacgccaaacttacaaag, reverse 
primer 5’: gtcagtgcccagatgt), Nkx6.1 (probe 5’: tctggttccagaaccgcagga, forward primer 5’: 
cggagagtcaggtca, reverse primer 5’: tgcgtgcttctttctc), MafA (probe 5’: cggcgcacgctcaagaaccg, 
forward primer 5’: catccgactgaaacagaag, reverse primer 5’: ctcgctctccagaatgtgccgctgc), MafB 
(probe 5’: cgcgtccagcagaaacatcacc, forward primer 5’: ccagtcgtgcaggtat, reverse primer 5’: 
tgcgtcttctcgttctc), NeuroD1 (probe: ABI 185747095, forward primer 5’: ccagcccactaccaatttgg, 
reverse primer 5’: gggttctgctcaggcaagaa). 
RNA-Sequencing (RNA-Seq):  Total RNA concentration and quality were measured using the 






Center with 30 million single end 100bp reads.  Dataset overlap was determined with a Fisher’s 
Exact test; significance was achieved with p-value < 0.05.  Data is available at GSE80444. 
ChIP-Sequencing (ChIP-Seq) comparative analysis:  Nkx2.2 (Dominguez Gutiérrez et al., 2016; 
GSE79725), Rfx6 (Piccand et al., 2014; GSE62844), and NeuroD1 (Tennant et al., 2013; 
GSE30298) ChIP-Seq datasets were aligned to mm9 and visualized using IGV (Robinson et al., 
2011; Thorvaldsdóttir et al., 2013).  Nkx2.2 direct targets were determined by cross-referencing 
the Nkx2.2
∆endo
 RNA-Seq data (adjusted p-value < 0.05, GSE80444) with the Nkx2.2 ChIP-Seq 
data (Dominguez Gutiérrez et al., 2016).  Dataset overlap was determined with a Fisher’s Exact 
test; significance was achieved with p-value < 0.05. Rfx6 bound genes contain Rfx6 binding 
within 100kb of TSS (Piccand et al., 2014; GSE62844). NeuroD1 bound genes contain NeuroD1 
binding within 100kb of TSS (Tennant et al., 2013; GSE30298).  Gene ontology (GO) analysis 











Figure 2-1. Nkx2.2 is ablated specifically in the endocrine lineage in Nkx2.2
∆endo
 mice. (A) 
Nkx2.2 gene expression is decreased at E15.5 (Control n=3, Nkx2.2
∆endo
 n=6) and E18.5 
(Control n=6, Nkx2.2
∆endo
 n=4). (B-C) Immunostaining for Nkx2.2 shows decreased expression 
in Nkx2.2
∆endo
 mice at P0 (n=3). (D-E) Immunostaining for Ngn3 shows no apparent changes in 
the Ngn3
+

















 mice recapitulate the Nkx2.2
KO
 phenotype. (A-H) Ghrl
+
 cells are 
increased, Ins
+
 cells are greatly reduced, and Gcg
+
 cells are decreased at E15.5 and P0 in 
Nkx2.2
∆endo
 mice (n=3). (I-J) Gast
+
 cells are reduced in Nkx2.2
∆endo 
embryos at E15.5 (n=3). (K-
L) SST
+
 cells are unchanged in Nkx2.2
∆endo 
mice at P0 (n=3). (M) Hormone gene expression 
changes recapitulate Nkx2.2
KO
 mice at E15.5 (Control n=3, Nkx2.2
∆endo
 n=6) and E18.5 (Control 
n=6, Nkx2.2
∆endo
 n=4). Ppy gene expression is increased at these time points. (N) Nkx2.2
∆endo
 























 embryos have shared and distinct gene expression 




 RNA-Seq experiments shows significant 
overlap of dysregulated genes with adjusted p-value < 0.05. (B) RNA-Seq confirms similar 




 embryos, relative to respective 





 embryos, relative to respective littermate controls. (D) qRT-PCR 
confirms decreases in MafA and MafB at E15.5 (Control n=3, Nkx2.2
∆endo
 n=6) and E18.5 
(Control n=6, Nkx2.2
∆endo
 n=4). (E) RNA-Seq shows unchanged Ngn3, NeuroD1, and Rfx6 gene 
expression in Nkx2.2
∆endo
 embryos, while Nkx2.2
KO
 embryos show downregulation, relative to 
respective littermate controls. (F) qRT-PCR confirms RNA-Seq results. Neurod1 and Rfx6 gene 
expression are unchanged at E15.5 and E18.5. Ngn3 gene expression is unchanged at E15.5 and 
increased at E18.5. (E15.5: Control n=3, Nkx2.2
∆endo
 n=3-6; E18.5: Control n=5-6, Nkx2.2
∆endo
 
n=4). (G-H) No Ngn3
+
 cells are detected at P0 (n=3). Adjusted p-values are shown for RNA-Seq 















Figure 2-4. Nkx2.2 bound and regulated genes are co-bound by Rfx6 and NeuroD1. (A) 
Comparison of Nkx2.2 bound and regulated genes and Rfx6 bound genes shows significant 
overlap. (B) Gene ontology (GO) analysis of genes with Nkx2.2 binding and regulation and Rfx6 
binding. (C) Comparison of Nkx2.2 bound and regulated genes and NeuroD1 bound genes shows 
significant overlap. (D) GO analysis of genes with Nkx2.2 binding and regulation and NeuroD1 
binding. (E) Nkx2.2, Rfx6, and NeuroD1 show overlapping binding peaks at Mlxipl locus (mm9 
chr5:135,580,783-135,615,792 shown). (F) Nkx2.2 and NeuroD1 show overlapping binding 
peaks at a region upstream of MafA (mm9 chr15:75,577,046-75,587,657 shown). (G) Nkx2.2 and 
Rfx6 show overlapping binding peaks upstream of Gast and within intron 1 (mm9 
chr11:100,186,915-100,199,407 shown). (H) Non-overlapping Nkx2.2, Rfx6, and NeuroD1 
binding peaks near G6pc2 locus (mm9 chr2:69,052,146-69,070,781 shown). (I) RNA-Seq shows 
decreased Mlxipl, MafA, Gast, and G6pc2 expression at E15.5 in Nkx2.2
∆endo
 embryos.  Adjusted 














 conditions. Ngn3, NeuroD1, and Rfx6 are not sufficient to allow for 










Supplemental Figure 2-1. Exocrine compartment and endocrine compartment size is 
unaffected in Nkx2.2
∆endo
 mice. (A-B) Immunostaining for Nkx2.2 shows decreased expression 
in Nkx2.2
∆endo
 embryos at E15.5 (n=3). (C) Endocrine compartment gene expression is 
unchanged at E15.5 (Control n=3, Nkx2.2
∆endo
 n=6) and E18.5 (Control n=6, Nkx2.2
∆endo
 n=4). 
(D-E) Immunostaining for amylase shows no changes in Nkx2.2
∆endo










Supplemental Figure 2-2. Nkx2.2
∆endo
 mice display endocrine specification defects at P0. (A-
D) Low magnification images showing increased Ghrl
+
 cells, and decreased Ins
+















Supplemental Figure 2-3. PP cells are increased in Nkx2.2
∆endo
 mice. (A-D) Immunostaining 
for PP shows increased PP
+
 cells at E15.5 and P0 in Nkx2.2
∆endo 





 cell. (E-F) Low magnification images showing increased PP
+
 cells at P0 in Nkx2.2
∆endo 




 cells normalized to total number of 
Tom
+












 cells in Nkx2.2
∆endo 
























 embryos, relative to respective littermate controls. (B) 
qRT-PCR confirms no changes in Nkx6.1, Pax4, or Pdx1 at E15.5 (Control n=3, Nkx2.2
∆endo
 















Supplemental Figure 2-5. Analysis of PP-related peptide expression in Nkx2.2
∆endo
 mice. (A-









 cells. (C) Pyy and Npy gene expression at E15.5 (Control n=3, 
Nkx2.2
∆endo
 n=6) and E18.5 (Control n=6, Nkx2.2
∆endo




 cells are found at 
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REQUIREMENT FOR THE NKX2.2 SD DOMAIN IN THE 
DEVELOPMENT AND MAINTENANCE OF BETA CELL FUNCTION  
 
Abstract 
Nkx2.2 is essential for pancreatic beta cell specification and also for the maintenance of beta cell 
identity.  The SD protein domain of Nkx2.2 mediates Nkx2.2 function during endocrine cell 
development; however, its role within endocrine progenitors and the beta cell has not been 
tested.  To identify SD domain function in the early transcriptional regulation of endocrine 
progenitors, the Ngn3-expressing progenitor population was isolated and RNA-Seq was 
conducted on Nkx2.2
SDmutant
 embryos.  Surprisingly, many genes associated with endocrine fate 
are differentially expressed even at this early stage of endocrine specification.  In addition, RIP-
Cre; Nkx2.2
SD/flox
 (βSD) mice were used to investigate SD domain function specifically within 
the beta cell.  These mice display hyperglycemia, glucose intolerance, and dysregulation of genes 
important for beta cell function.  Together, these results suggest the Nkx2.2 SD domain plays 
novel, essential roles in regulating the establishment of appropriate gene transcription early in the 
endocrine progenitor population and is also important within the beta cell itself. 
Introduction 
Nkx2.2 is expressed in the CNS, intestine, and pancreas and is important for the proper 
specification of multiple cell lineages:  neuronal populations in the CNS (Briscoe et al., 2000; 
Briscoe et al., 1999; Ericson et al., 1997; Pattyn et al., 2003; Qi et al., 2001; Zhou et al., 2001), 






endocrine cells (Prado et al., 2004; Sussel et al., 1998).  Furthermore, in each of these tissues, 
Nkx2.2 appears to function both as a transcriptional activator and repressor.  For pancreatic 
endocrine cell development, Nkx2.2 repressor function appears to be responsible for immature 
beta cell differentiation; however, Nkx2.2 activator function may be required for beta cell 
maturation (Doyle et al., 2007). 
Nkx2.2 exerts its transcriptional regulation through three conserved protein domains:  the 
homeodomain, tinman (TN) domain, and NK2 specific (SD) domain.  The homeodomain 
recognizes and binds DNA (Kim and Nirenberg, 1989; Tsao et al., 1995; Watada et al., 2000).  
The TN domain mediates interaction between Nkx2.2 and the transcriptional co-repressor Grg3 
(Doyle et al., 2007; Papizan et al., 2011).  Nkx2.2
TNmutant
 mice display defective beta cell 
formation and transdifferentiation to the alpha cell lineage, demonstrating the requirement for 
this domain in establishing beta cell fate (Papizan et al., 2011).  Lastly, the SD domain is 
conserved across species and is the defining feature of the NK2 family of proteins; however, its 
function has not been well characterized.  In vitro studies demonstrated that the SD domain may 
be involved in masking C-terminal-driven transcriptional activation and does not contribute to 
DNA binding (Watada et al., 2000).   





 mice) has provided insight into the role of the SD domain in mediating Nkx2.2 
function (Fig. 3-1) (Levine et al., in preparation).  Analysis of Nkx2.2
SDmutant
 mice has revealed a 
critical role for this domain during pancreatic beta cell specification.  These mice display 






required to establish monohormonal cell identity (Levine et al., in preparation).  While the SD 
domain mediates Nkx2.2 function during beta cell specification, this domain appears to be 
dispensable for Nkx2.2-mediated cell fate induction in the developing CNS.  Nkx2.2 is important 
for the specification of serotonergic neurons (Briscoe et al., 1999; Pattyn et al., 2003), V3 
interneurons (Briscoe et al., 2000; Ericson et al., 1997), and oligodendrocyte maturation (Qi et 
al., 2001; Zhou et al., 2001). However, these cell fates are unchanged in Nkx2.2
SDmutant
 mice 
(Levine et al., in preparation).  This suggests the SD domain is responsible for exerting pancreas-
specific functions of Nkx2.2 transcriptional regulation. 
It has recently been discovered that Nkx2.2 is required not only for establishing beta cell fate, but 
also maintaining beta cell identity.  Dominguez Gutiérrez et al. (2016) used RIP-Cre; 
Nkx2.2
flox/flox




mice) to determine the role of 
Nkx2.2 within the developing and mature beta cell.  These mice display glucose intolerance and 













polyhormonal cells can also be readily observed in Nkx2.2
∆beta 
mice.  This suggests Nkx2.2 is 
necessary for proper expression of genes important for beta cell function, and Nkx2.2 is required 
for the maintenance of monohormonal cell fate (Dominguez Gutiérrez et al., 2016). 
While the Nkx2.2 SD domain is necessary for establishing a monohormonal cell fate during beta 
cell formation, its transcriptional role specifically within the endocrine progenitor and its 
function within the beta cell have yet to be assessed.  In this study, we sought to identify the 






contribution of the SD domain in mediating the role of Nkx2.2 in maintaining beta cell function 
and/or identity. 
Results 
Transcriptional profiling of Nkx2.2
SDmutant
 endocrine progenitors 
Since the Ngn3
+
 endocrine progenitor lineage is a critical window for beta cell specification 
(Chapter 2), identifying the transcriptional program regulated by the Nkx2.2 SD domain at this 
stage of pancreas development was of particular interest.  To determine the transcriptional profile 





mice) (Arnes et al., 2012b; Lee et al., 2002; 
Levine et al., in preparation).  The Ngn3-EGFP allele marks all Ngn3-expressing endocrine 
progenitor cells with EGFP.  Since EGFP has a half-life of over 24h, signal may persist 
following initial expression (Barrow et al., 2005).  EGFP
+ 
cells were isolated using FACs from 
E14.5 and E15.5 embryonic pancreata since this is a time of high Ngn3 expression during 
development (Fig. 3-2A) (Schwitzgebel et al., 2000).  FACs-isolation of the EGFP
+
 cells using 
this allele likely isolates both Ngn3
+
 endocrine progenitors and their immediate descendants after 
Ngn3 becomes repressed.  
Since approximately1500-3000 cells could be obtained from each pancreas, EGFP
+
 cells from 
six pancreata (five E15.5 pancreata and one E14.5 pancreas) of like-genotypes were pooled to 
gain sufficient quantity for RNA-Seq (n=2). 
Clustering of RNA-Seq samples indicated there was separation between control and 
Nkx2.2
SDmutant






(Ins1 and Ins2) gene expression, and a decrease in the pan-endocrine marker Chromogranin A 
(Chga) (Fig. 3-3, Table 3-1).  In addition, Sst and Ghrl gene expression is increased; however, 
Gcg and Ppy are unchanged (Fig. 3-3, Table 3-1).  While multiple pancreatic hormones are 
dysregulated, endocrine transcription factors are also differentially expressed.  Crucial mature 
and immature beta cell transcription factors, such as Nkx6.1, MafA, and MafB, show decreased 
expression (Fig. 3-4, Table 3-1).  Furthermore, the alpha cell transcription factor Arx is 
upregulated (Fig. 3-4, Table 3-1).  These gene expression changes are consistent with the 
decreased beta cell population and the polyhormonal phenotype that is observed in Nkx2.2
SDmutant
 
mice, indicating the SD domain mediates transcriptional regulation of endocrine genes early in 
development. 
Role of the Nkx2.2 SD domain in the maintenance of beta cell function 
To identify Nkx2.2 SD domain function within the beta cell, we generated RIP-Cre; 
Nkx2.2
SD/flox
; Rosa26-Tomato (βSD) mice.  βSD mice display no detectable changes in body 
weight in males or females (Fig. 3-5A,B).  However, these mice display elevated ad libitum (ad 
lib) blood glucose levels in males and females, as early as 3 and 2 weeks of age (wk), 
respectively (Fig. 3-5C,D).  βSD males and females also display glucose intolerance at 4wk (Fig. 
3-6).  These metabolic defects suggest the Nkx2.2 SD domain is important in maintaining beta 
cell function and glucose homeostasis. 
To determine the regulatory pathways within the beta cell that are affected by loss of the SD 
domain, we performed RNA-Seq analysis on isolated islets in 7.5 week-old βSD mice (Fig. 3-






cell function are differentially expressed (Fig. 3-7C).  These genes encode important beta cell 
proteins including beta cell transcription factors and proteins involved in glucose sensing, insulin 
processing/secretion, insulin granule synthesis, and the glycolytic pathway (Fig 3-7C).  
Interestingly, unlike the global SD mutant, progenitor cell markers or factors that are important 
for alternate endocrine cell fates, including Ngn3, Sox9, Arx, and Hhex, are not affected (Fig. 3-
7D).  This indicates that the Nkx2.2 SD domain is necessary for mediating the transcriptional 
regulation of genes important for beta cell function. 
To confirm the RNA-Seq results, I performed qRT-PCR on islets isolated at 4 weeks of age.  
This time point was chosen to minimize any potential secondary effects that could result from a 
hyperglycemic state on gene regulation.  This analysis revealed minor changes in pancreatic 
hormone gene expression in βSD mice, including decreased Ins2 expression and increased Sst 









 cell numbers and there was no observed increase in polyhormonal cell 
frequency (Fig. 3-8B-G).  In addition, while there was an increase in Gast gene expression, Gast 
immunostaining shows no Gast
+
 cells present in βSD or control pancreata despite positive Gast 
staining in an E15.5 control (Fig. 3-8H-J).  This is consistent with previous observations that the 
G cell population is restricted to the embryonic pancreas (Suissa et al., 2013).  In contrast to its 
role in establishing monohormonal cell fate during embryogenesis, these results suggest the SD 
domain is dispensable for the Nkx2.2-mediated maintenance of monohormonal beta cell identity. 
Consistent with the RNA-Seq analysis, qRT-PCR also confirmed there were no changes in Ngn3, 






downregulated in βSD mice.  This included decreased in Insm1, Pdx1, Nkx2.2, Nkx6.1, and Glut2 
expression (Fig. 3-10).  There was also a trending decrease in MafA gene expression (Fig. 3-10).  
These proteins are required for numerous features of beta cell function.  For example, Glut2 is 
the glucose transporter present in pancreatic beta cells, and is therefore essential for glucose-
stimulated insulin secretion.  Defects in these proteins and the processes of which they are 
involved could explain the metabolic perturbations observed in βSD mice, including 
hyperglycemia and glucose intolerance.  This data is indicative of a critical role for the Nkx2.2 
SD domain in maintaining the expression of proteins important for beta cell function. 
Discussion 
Nkx2.2 SD domain mediates early transcriptional regulation in endocrine progenitors  
The Nkx2.2 SD domain plays an important function in establishing beta cell fate and 
monohormonal identity.  By conducting RNA-Seq on the endocrine progenitor population of 
Nkx2.2
SDmutant
 mice, the transcriptional profile of this population and early targets of Nkx2.2 
could be identified.  Surprisingly, changes in pancreatic hormone gene expression were observed 
at this early stage, likely reflective of the polyhormonal cell phenotype yet to form.  In addition, 
factors important for the proper differentiation of the beta cell lineage were decreased, including 
Nkx6.1, MafA, and MafB.  These results suggest that the Nkx2.2 SD domain is exerting an effect 
on transcriptional regulation early in the process of endocrine differentiation. 
The Ngn3
+
 endocrine progenitor lineage has been implicated as a critical window for beta cell 
formation (Chapter 2).  In addition, the Nkx2.2 SD domain has been found to play a role in 






the transcriptional changes associated with altered endocrine fate occur very early in the process 
of endocrine differentiation, shortly following Ngn3 expression.  These results may have 
implications for optimizing in vitro beta cell differentiation protocols which currently enrich for 
Ngn3
+
 cells and rely on endocrine progenitor potential. 
Nkx2.2 SD domain is necessary within beta cells for proper function  
Since Nkx2.2 has recently been shown to maintain beta cell identity and function, βSD mice 
were used to investigate the role of the SD domain in this process.  βSD mice display 
hyperglycemia and glucose intolerance.  In addition, many genes important for beta cell function 
are dysregulated.  This is consistent with the phenotype observed in Nkx2.2
∆beta
 mice, which also 
show hyperglycemia, glucose intolerance, and transcriptional changes at a young age 
(Dominguez Gutiérrez et al., 2016).  These results indicate the Nkx2.2 SD domain mediates 
Nkx2.2 function within the beta cell. 
Interestingly, although Nkx2.2 is required within the beta cell to maintain monohormonal fate, 
the SD domain does not appear to be involved in this function once beta cells are formed.  
Nkx2.2
∆beta
 mice contain polyhormonal cells (Dominguez Gutiérrez et al., 2016); however, βSD 
mice do not show detectable increases in polyhormonal cell frequency.  This is in contrast to the 
role of the SD domain during embryonic development and its function in establishing 
monohormonal cell fate (Levine et al., in preparation).  These results may be indicative of an 







Since the RIP-Cre allele was employed in the βSD mice, it is important to note that 
recombination is likely occurring in immature beta cells before birth.  The metabolic 
perturbations observed in βSD mice could reflect defects in the beta cell maturation process or 
they may be reflecting defects acquired after maturation.  Future experiments could be conducted 
using the MIP-CreER allele and tamoxifen to induce recombination in adult mice (Wicksteed et 
al., 2010).  This would elucidate SD domain function within beta cells that have already finished 
their maturation process. 
Beta cell loss of function is thought to occur during diabetes progression (Guo et al., 2013; 
Talchai et al., 2012).  These results show that the Nkx2.2 SD domain may be important in 
preventing a similar process and ensuring proper expression of genes that are crucial for glucose 
homeostasis. 
Materials and Methods 
Animal maintenance  





 mice were genotyped as previously published (Arnes et al., 2012b; Lee 




, and R26R-Tomato 
(B6.Cg-Gt(ROSA)26-Sor
tm14(CAG-tdTomato)Hze
/J) mice were genotyped as previously published 
(Herrera, 2000; Levine et al., in preparation; Madisen et al., 2010; Mastracci et al., 2013).  
Animal maintenance and procedures were conducted in accordance with a Columbia University 






Fluorescence-activated cell sorting (FACs) 
Embryonic pancreata were dissected at E14.5 and E15.5 into ice cold PBS.  Pancreata were 
dissociated in Accumax (Invitrogen) with 25µg DNase I (Qiagen) at 37°C for 30min.  Reaction 
was stopped with 2% fetal bovine serum (FBS)/RPMI 1640 with 25µg DNase I (Qiagen).  Cells 
were washed in DPBS without ions and resuspended in 350µL DPBS without ions with 1µL 
DAPI (Invitrogen TD21490).  Cells were FACs-isolated at the Columbia HICCC FACs facility 
into 750µL Trizol-LS (Invitrogen).  Samples were stored at -80°C until RNA extraction. 
Endocrine Progenitor RNA analysis 
FACs-isolated cells RNA extraction:  The total volume of FACs-isolated cells was brought to 
1mL with water.  200uL chloroform was added and samples were homogenized via vortexing.  
Phase lock gel tubes (Eppendorf) were used to isolate the aqueous layer.  Total RNA was then 
isolated using the Qiagen RNeasy Micro kit:  cells isolated from six embryonic pancreata were 
pooled for each n during RNA extraction at the initial column-binding step in the Qiagen 
RNeasy micro kit protocol.  Controls were Ngn3-EGFP/+; Nkx2.2




”) were Ngn3-EGFP/+; Nkx2.2
SD/LacZ
 mice.   
RNA-Sequencing (RNA-Seq):  Total RNA concentration and quality were measured using the 
Agilent Bioanalyzer RNA Pico chip.  Amplified cDNA was synthesized using the Nugen 
Ovation RNA-Seq System V2 kit (Part No. 7102).  Total cDNA concentration and quality were 
measured using the Agilent Bioanalyzer DNA 1000 chip.  RNA-Seq was performed by the 
Columbia Genome Center with 30 million single end 100bp reads (n=2, each n comprised of six 






adjusted p-value < 0.05 and 457 genes with an unadjusted p-value < 0.05; both sets of genes 
were considered in subsequent analysis.   
Islet RNA analysis 
Islet isolation and RNA extraction:  Pancreata were perfused through the common hepatic bile 
duct with 1mg/mL Collagenase P (Roche)/M199 medium (Invitrogen).  Pancreata were dissected 
and incubated at 37°C for 16min.  Samples were washed multiple times with 10% fetal bovine 
serum (FBS; Gemini Bio Products)/M199.  Histopaque (Sigma) and M199 were used to separate 
islets on a gradient and islets were subsequently picked under a dissection microscope.  Islets 
were disrupted via vortexing, and total RNA was isolated following the Qiagen RNeasy Micro 
kit. 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis:  A 
normalized starting quantity of RNA (200ng-1µg) isolated from islets and random hexamers 
were used to synthesize cDNA following the SuperScript III reverse transcriptase protocol 
(Invitrogen 18080-044).  qRT-PCR was performed using 200ng cDNA and master mix 
(Eurogentec) and analyzed using the BioRad CFX96 Real-Time System.  Genes were 
normalized to CyclophilinB (probe 5’: tggtacggaaggtggag, forward primer 5’: 
gcaaagttctagagggcatgga, reverse primer 5’: cccggctgtctgtcttggt) and to littermate controls.  An n 
≥ 3 was used at all ages.  All values are expressed as mean ± SEM.  Statistical analysis was 
performed using two-tailed student’s unpaired t-test.  Significance was achieved with p-value < 
0.05.  Controls were RIP-Cre/+; Nkx2.2
flox/+








R26R-Tomato/+ (n=4 females), and mutants (βSD) were RIP-Cre/+; Nkx2.2
SD/flox
; R26R-
Tomato/+ (n=4 females). 
Applied Biosystems TaqMan AODs:  Insulin1 (Mm01950294_s1), Insulin2 (Mm00731595_gH), 
Glucagon (Mm00801712_m1), Pancreatic polypeptide (Mm00435889_m1), Ghrelin 
(Mm00445450_m1), Somatostatin (Mm00436671_m1), Gastrin (Mm00439059_g1), 
ChromograninA (Mm00514341_m1), Arx (Mm00545903_m1), Pdx1 (Mm00435565_m1), Glut2 
(Mm00446229_m1), Insm1 (Mm02581025_s1). 
Sybr green primers:  Hhex (forward primer 5’: tcagaatcgccgagctaaat, reverse primer 5’: 
ctgtccaacgcatccttttt).  
Applied Biosystems Primer/TaqMan Probe sets:  Nkx2.2 (probe 5’: ccattgactctgccccatcgctct, 
forward primer 5’: cctccccgagtggcagat, reverse primer 5’: gagttctatcctctccaaaagttcaaa), 
Neurogenin3 (probe 5’: cctgcgcttcgcccacaact, forward primer 5’: gacgccaaacttacaaag, reverse 
primer 5’: gtcagtgcccagatgt), Nkx6.1 (probe 5’: tctggttccagaaccgcagga, forward primer 5’: 
cggagagtcaggtca, reverse primer 5’: tgcgtgcttctttctc), MafA (probe 5’: cggcgcacgctcaagaaccg, 
forward primer 5’: catccgactgaaacagaag, reverse primer 5’: ctcgctctccagaatgtgccgctgc). 
RNA-Sequencing (RNA-Seq):  Total RNA concentration and quality were measured using the 
Agilent Bioanalyzer RNA Nano chip.  RNA-Seq was performed by the Columbia Genome 
Center with 30 million single end 100bp reads.  Controls were RIP-Cre/+; Nkx2.2
flox/+
; R26R-
Tomato/+ (n=1 male) and RIP-Cre/+; Nkx2.2
flox/+






mutants (βSD) were RIP-Cre/+; Nkx2.2
SD/flox
; R26R-Tomato/+ (n=2 males) and RIP-Cre/+; 
Nkx2.2
SD/flox
; R26R-+/+ (n=1 female). 
Glucose tolerance test 
Mice were fasted for 12-16h.  After fasting, mice were given an intraperitoneal (IP) injection of 
20% glucose (2mg/g body weight).  Blood glucose was measured at 0, 15, 30, 45, 60, 90, 120, 
150, and 180 minutes (min) following IP injection.  Area under the curve (AUC) was calculated.  
An n ≥ 3 was used at all ages.  All values are expressed as mean ± SEM.  Statistical analysis was 
performed using two-tailed student’s unpaired t-test.  Significance was achieved with p-value < 
0.05.  
Immunohistochemistry 
Fixation:  Adult pancreata were dissected at 4.5 weeks of age.  Samples were fixed in 10% 
neutral-buffered formalin (VWR) at 4°C for 2-4h, and then transferred to 70% ethanol.  Samples 
were embedded in paraffin and 5µm sections were taken and stored at room temperature (RT). 
Staining:  Sections were subjected to antigen retrieval with 10mM sodium citrate (pH=6), boiling 
for 20min.  Following antigen retrieval, sections were returned to RT for 20min.  Sections were 
washed in PBS and 0.1% Triton/PBS (PBST) and blocked in 2% donkey serum (DS)/PBST for 
30min at RT.  Primary antibody was diluted in 2% DS/PBST and incubated on sections 
overnight at 4°C.  Sections were washed in PBS and PBST and incubated 2-3h at RT with 
secondary antibody (Jackson Immuno Research) diluted in 2% DS/PBST at 1:500.  Sections 






at 1:1000 for 15 min at RT.  Sections were washed in PBS and mounted with fluorescent 
mounting medium (DAKO S3023). 
Primary antibodies:  guinea pig α-Insulin (DAKO, 1:500), rabbit α-Glucagon (DAKO, 1:800), 
rabbit α-Pancreatic Polypeptide (Zymed/Invitrogen, 1:200), rabbit α-Somatostatin (Phoenix 
Pharmaceuticals, 1:200), rabbit α-Gastrin (Cell Marque, 1:200). 
Microscopy:  Images were taken using a Zeiss Confocal LSM 710 microscope and processed 








Figure 3-1. Mutation of the Nkx2.2 SD domain.  Amino acid substitutions present in 
Nkx2.2
SDmutant











Figure 3-2. Endocrine progenitor isolation and RNA-Seq analysis.  (A) Representative FACs 
plot of isolated EGFP
+
 cells. (B) Cluster diagram displaying control and Nkx2.2
SDmutant
 (SD) 












 endocrine progenitors show changes in pancreatic hormone gene 
expression.  RNA-Seq data showing decreased Chga, Ins1, and Ins2 and increased Sst and Ghrl 
gene expression.  Unadjusted p-values: (**) P < 0.01; (***) P < 0.001. Adjusted p-values: (##) P 









Figure 3-4. Beta and alpha cell transcription factors are changed in Nkx2.2
SDmutant
 
endocrine progenitors.  RNA-Seq data showing decreased Nkx6.1, MafA, and MafB, and 
increased Arx gene expression.  MafA gene expression was not detected in Nkx2.2
SDmutant
 









Figure 3-5. βSD mice are hyperglycemic early in life. (A) βSD male body weight is not 
changed. (B) βSD female body weight is not changed. (C) βSD males display elevated ad libitum 
(ad lib) blood glucose levels at 3 and 6 weeks of age. (D) βSD females display elevated ad lib 
blood glucose at 2, 3, and 6 weeks of age. The (n) for each condition is displayed at the base of 









Figure 3-6. βSD mice are glucose intolerant at 4 weeks. (A) βSD males are glucose intolerant 
at 4 weeks of age (Control n=6, βSD n=6). (B) βSD females are glucose intolerant at 4 weeks of 















Figure 3-7. RNA-Seq of isolated islets from βSD mice at 7.5 weeks of age. (A) Cluster 
diagram of RNA-Seq samples. (B) Pancreatic hormones show minor changes in gene expression 
in βSD mice. (C) β cell transcription factors, glucose sensing, insulin processing/secretion, 
insulin granule features, and glycolytic pathway genes are differentially expressed in βSD mice. 
(D) Non-beta cell transcription factors are unchanged in βSD mice. (Control n=3, 2 males and 1 
female; βSD n=3, 2 males and 1 female). Unadjusted p-values (pval) and adjusted p-values 














Figure 3-8. βSD mice show minor changes in hormone expression. (A) qRT-PCR on isolated 









 co-positive cells appear unchanged in βSD mice at 4.5wk (n=3). 
(D-E) SST
+




 co-positive cells appear unchanged in βSD mice at 4.5wk 
(n=3). (F-G) PP
+




 co-positive cells appear unchanged in βSD mice at 
4.5wk (n=3). (H) E15.5 pancreas as a positive control for Gast immunostaining (n=3). (I-J) 
Gast+ cells are not detected in control or mice at 4.5wk (n=3). (*) P < 0.05; (**) P < 0.01; (***) 









Figure 3-9. Select pancreatic transcription factors are unchanged in βSD mice. qRT-PCR on 









Figure 3-10. β cell factors are decreased in βSD mice. qRT-PCR on isolated islets at 4 weeks 












 endocrine progenitor RNA-Seq.  RNA-Seq fold change of select 
pancreas-related genes in Nkx2.2
SDmutant
 endocrine progenitors relative to littermate controls. 








CONCLUSIONS AND PERSPECTIVES 
 
My studies into the role of Nkx2.2 and its SD domain have provided insight into the timing and 
mechanism of beta cell specification, as well as the maintenance of beta cell function.  Ngn3-
driven ablation of Nkx2.2 in Nkx2.2
∆endo
 mice revealed a critical window for inducing beta cell 
fate.  Nkx2.2
∆endo
 mice displayed defective beta cell differentiation and altered specification of 
other endocrine lineages; these results were consistent with the Nkx2.2
-/-
 phenotype.  However, 
preserved expression of Ngn3, NeuroD1, and Rfx6 has revealed a unique requirement for Nkx2.2 
during this developmental window.  ChIP-Seq analyses have also revealed co-occupancy of 
Nkx2.2 with Rfx6 and NeuroD1 at loci near endocrine-related genes.  Lastly, the SD domain of 
Nkx2.2 appears to function within endocrine progenitor cells and beta cells.  Early during 
endocrine specification, the SD domain is necessary for proper transcriptional regulation of 
endocrine fate genes to establish monohormonal cell fate.  Within the beta cell, the SD domain is 
no longer required to maintain monohormonal cell fate.  However, it is necessary for the proper 
expression of beta cell functional genes, with βSD mice displaying hyperglycemia and glucose 
intolerance.  Overall, these results have implications for in vitro beta cell differentiation 
protocols and reveal processes that may be involved in diabetes progression. 
Timing of beta cell specification 
Ngn3 marks the endocrine progenitor population, and each Ngn3
+
 cell has traditionally been 
thought to be multipotent.  Recent evidence has suggested there are temporally-regulated 
endocrine fate competence windows (Johansson et al., 2007), and a recent model has proposed 
each Ngn3
+






Since Nkx2.2 is an essential factor for beta cell specification and is expressed early and 
throughout pancreas development, these thesis studies sought to determine the timing of beta cell 
specification through conditional ablation of Nkx2.2 within the Ngn3 lineage.  The phenotype of 
Nkx2.2
∆endo
 mice suggests Nkx2.2 is required downstream of Ngn3, and suggests that the Ngn3 
lineage is a critical developmental window for beta cell specification.   
It was surprising that Nkx2.2 function within the pancreatic progenitor population was not 
sufficient to induce beta cell fate.  However, these results are consistent with ablation of other 
pancreatic transcription factors downstream of Ngn3 in recent studies.  Ngn3-Cre; Rfx6
flox/flox
 
mice and Ngn3-Cre; Nkx6.1
flox/flox
 mice display defective beta cell differentiation (Piccand et al., 
2014; Schaffer et al., 2013).  These studies, in combination with the results of this work, 
demonstrate the importance of the Ngn3 lineage for endocrine specification. 
While Nkx2.2 is essential downstream of Ngn3 for beta cell specification, Nkx2.2 function 
within the Pdx1
+
 pancreatic progenitor has yet to be investigated.  Since there is no rescue of the 
beta cell lineage in Nkx2.2
∆endo
 mice, it is clear that Nkx2.2 function within the pancreatic 
progenitor is not sufficient for beta cell specification.  However, Nkx2.2 may still function early 
in the pancreatic progenitor, upstream of Ngn3, to prime the cell for a particular endocrine fate.  
Future work could address this question by employing an “addback” approach, where Nkx2.2 
expression is induced by an Ngn3-driven allele within an Nkx2.2
-/-
 background.  If any defects 
were present in the beta cell lineage, this would demonstrate that Nkx2.2 is not only playing an 
early role in beta cell specification, but this would also reveal that endocrine specification can be 






These studies have shown that the Ngn3 lineage is essential for beta cell specification and that 
Nkx2.2 is uniquely required during this window of development.  This has implications for 
optimizing differentiation protocols, where prolonged expression of developmental transcription 
factors, including Nkx2.2, Rfx6, and Nkx6.1, are likely to be essential to establish a fully 
functional beta cell in vitro. 
Nkx2.2, Rfx6, and NeuroD1 co-occupancy 
Transcription factors may function in a hierarchical manner, where one transcription factor leads 
to activation or repression of a downstream transcription factor to influence cell fate.  These 
relationships have been observed in single knockout mice where downstream factors display 
altered expression in response to loss of an upstream regulator.  For example, Nkx2.2
-/-
 mice 
display decreased expression of Ngn3, NeuroD1, and Rfx6 (Chao et al., 2007) (Fig. 2-3E).  Since 
each of these factors is individually required for beta cell specification, it’s possible that Nkx2.2 
affects beta cell fate via these downstream regulators.  While Nkx2.2
∆endo
 mice display complete 
retention of the Ngn3, NeuroD1, and Rfx6 expression, beta cell fate is not restored, indicating 
that Nkx2.2 is uniquely required in the Ngn3 lineage for beta cell specification. 
These studies also show significant overlap of Nkx2.2 bound and regulated genes with Rfx6 
bound genes and NeuroD1 bound genes.  These shared targets are related to endocrine cell fate 
and function, suggesting Nkx2.2 is not only upstream of Rfx6 and NeuroD1, but also cooperates 
with them during endocrine specification.  Numerous co-binding patterns between Nkx2.2 and 
Rfx6 or NeuroD1 were observed near target genes.  Both overlapping binding peaks and distinct 






occupancy.  These results are consistent with motif analysis conducted on the Nkx2.2 ChIP-Seq 
data (GSE79725).  This analysis revealed Rfx4/5/6 and NeuroD1 motifs near Nkx2.2 binding 
sites (Dominguez Gutiérrez et al., 2016), indicating that Nkx2.2 is likely to share targets with 
Rfx6 and NeuroD1.   
Transcription factor co-occupancy at endocrine related genes also appears to be conserved in 
humans.  A study conducted by Pasquali et al. (2014) characterized pancreatic transcription 
factor binding in human islets.  These binding peaks were cross-referenced with histone 
modifications, enabling identification of promoter and enhancer regions.  Multiple transcription 
factor ChIP-Seqs were analyzed, including PDX1, NKX2.2, and NKX6.1.  This analysis 
revealed many instances of co-occupancy at enhancer regions.  In addition, motifs found near 
these regions were those of RFX and NEUROD1 (Pasquali et al., 2014).  This indicates 
conservation of pancreatic transcription factor co-occupancy across species. 
Although Nkx2.2 and Rfx6/NeuroD1 co-binding suggests cooperation between these 
transcription factors to regulate gene transcription, the mechanism of such cooperation has not 
been tested.  Functional redundancy may exist, where Nkx2.2, Rfx6, and NeuroD1 function 
independently of each other to regulate a common target.  For this reason, further experiments 
need to be conducted to first identify the presence of functional cooperation and also to 
determine the mechanism of such cooperation.  Potential manners of cooperative action could 
include:  direct binding in a common complex, factor-dependent recruitment of another (direct or 






experiments, and high order chromatin structure could be analyzed with chromatin interaction 
analysis paired-end tag sequencing (ChIA-PET). 
These studies reveal co-occupancy of Nkx2.2, NeuroD1, and Rfx6 near endocrine-related target 
genes.  Since each of these factors is individually necessary for beta cell specification (Naya et 
al., 1997; Smith et al., 2010; Sussel et al., 1998), this co-occupancy implies cooperation to 
promote beta cell fate.  In vivo analysis of Nkx2.2
∆endo
 mice indicates a unique requirement for 
Nkx2.2 within the endocrine progenitor lineage, suggesting prolonged expression of Nkx2.2 is 
necessary for beta cell differentiation.  These findings are important to consider for in vitro 
differentiation methods; timing and length of transcription factor co-expression may be crucial 
for combinatorial regulation of endocrine fate genes. 
Role of Nkx2.2 SD domain in establishing endocrine fate 
Nkx2.2
SDmutant
 mice display defective beta cell differentiation and polyhormonal cells (Levine et 
al., in preparation).  To determine the transcriptional profile of Nkx2.2
SDmutant
 endocrine 
progenitors, RNA-Seq was performed on isolated Ngn3-EGFP
+
 cells.  This analysis revealed 
many transcriptional changes in genes related to endocrine fate, including pancreatic hormones 
and beta cell functional genes.  These changes are consistent with the endocrine defects observed 
in Nkx2.2
SDmutant
 mice.  This analysis reveals an important role for the SD domain and Nkx2.2 in 
the early regulation of endocrine genes, either prior to or shorty after Ngn3 expression.  These 
results are also consistent with our other studies identifying the Ngn3
+
 endocrine progenitor 






Future experiments will determine the mechanism of Nkx2.2 transcriptional regulation during 
early endocrine development.  Wang et al. (2015) recently identified poised enhancers near 
lineage-specific genes in the gut tube stage of hESC differentiation.  They also found these 
poised enhancer states were predictive of transcriptional response, and suggested pioneer 
transcription factors, such as FOXA1/2,  may affect chromatin accessibility and cell fate prior to 
lineage acquisition (Wang et al., 2015).  A similar phenomenon may be occurring with Nkx2.2-
mediated transcriptional regulation.  Nkx2.2 and its SD domain may prime the chromatin 
landscape for a particular endocrine cell fate, thereby enabling the rapid transcriptional changes 
observed in Ngn3 endocrine progenitors.  Cell fate choice may be dictated by the open or closed 
chromatin regions established by Nkx2.2 and/or by the cofactors present in a particular cell. 
An additional regulatory mechanism could involve the Nkx2.2 SD domain mediating repression 
of alternative endocrine fate genes.  If the SD domain is responsible for repressing non-beta cell 
fate genes within developing beta cells, then in Nkx2.2
SDmutant
 mice, this repressive regulation 
could be lost, leading to polyhormonal cell formation. 
Gaining a better understanding of the timing and mechanism of beta cell fate induction, with 
respect to Ngn3 expression, has implications for in vitro differentiation research.  Ngn3
+
 cells are 
commonly considered to be multipotent for all endocrine lineages; however, their chromatin 
landscape may already be primed toward particular endocrine fates. 
Role of Nkx2.2 SD domain in maintaining beta cell function 
Dominguez Gutiérrez et al. (2016) have recently shown that Nkx2.2 is required within the 






2016).  The Nkx2.2 SD domain is also important in establishing monohormonal beta cell fate 
during development and mediating the pancreas-specific functions of Nkx2.2 (Levine et al., in 
preparation).  In these studies, SD domain function within the mature beta cell was explored 
using βSD mice.  These mice displayed defective glucose homeostasis, indicating the SD domain 
is required within the beta cell for proper function.  In addition, many genes related to beta cell 
function were also dysregulated, suggesting the SD domain mediates Nkx2.2 transcriptional 
regulation of targets important for beta cell function.  These results are consistent with a model 
where the SD domain mediates pancreas-specific functions of Nkx2.2, in contrast to Nkx2.2 
function in neuronal fate decisions in the CNS. 
Surprisingly, βSD mice do not display polyhormonal cells. This is in contrast to the Nkx2.2
∆beta
 
mice, indicating the SD domain is dispensable for maintaining monohormonal cell fate.  This 
also suggests that the defective regulation of blood glucose observed in Nkx2.2
∆beta
 mice is likely 
not contingent on its polyhormonal phenotype.  These results also reveal a context-dependent 
role of the Nkx2.2 SD domain, where this domain is required for establishing but not 
maintaining monohormonal endocrine cell fate.  This context-dependency could be controlled by 
the different chromatin landscape or by the different cofactors expressed in endocrine 
progenitors versus beta cells.  As proposed earlier, the SD domain could establish 
monohormonal beta cell fate by repressing non-beta cell genes.  These genes, once repressed, 
may not require active repression within the beta cell once formed.  In Nkx2.2
∆beta
 mice, the 
polyhormonal cells observed could be caused by inappropriate expression of transcriptional 







The Nkx2.2 SD domain may exert its function by mediating interactions between Nkx2.2 and 
other proteins.  There is evidence that suggests the SD domain is necessary for interaction 
between Nkx2.2 and the DNA methyltransferase Dnmt1 (Levine et al., in preparation).  Dnmt1 is 
thought to be a maintenance methyltransferase since it binds preferentially to hemi-methylated 
DNA (Fatemi et al., 2001; Goyal et al., 2006; Leonhardt et al., 1992).  Maintenance of 
methylation is important during cell cycle progression, since this process involves DNA 
replication and synthesis of nascent DNA strands.  Without propagation of methylation marks, 
this epigenetic information could be lost during cell cycle progression (Goyal et al., 2006; 
Hermann et al., 2004).  Both pancreatic progenitors and newly formed beta cells undergo 
proliferation.  Pancreatic progenitors proliferate early in pancreas development to expand the 
progenitor population and establish proper organ size (Stanger et al., 2007).  Newly formed beta 
cells also proliferate to expand the beta cell population during the end of gestation and also in 
neonatal life (Bouwens and Rooman, 2005).  Given these instances of proliferation during 
development and cell fate determination, Nkx2.2 and its SD domain may be responsible for 
recruiting Dnmt1 to maintain methylation near endocrine genes.  This interaction may be 
required both before and after beta cell formation to establish monohormonal cell fate and to 
maintain proper expression of beta cell function genes. 
It is also likely that the SD domain facilitates interactions with other proteins as well.  Recently, 
mass spectrometry (mass spec) analysis was conducted to identify interactors with Nkx2.2-WT 
and Nkx2.2-SDmutant protein in the Min6 β cell line (Balderes, unpublished data).  Preliminary 
analysis has identified Nkx2.2 interactions with chromatin remodeling proteins, many of which 






including Chd3/4/5, Ddx5, Hdac1/2, Mta1/2/3, Rbbp4/7, and Gatad2a/2b (Balderes, unpublished 
data).  Nkx2.2-SDmutant protein appears to have reduced interactions with Chd3/5, Mta1/2/3, 
Rbbp4/7, and Gatad2a/2b (Balderes, unpublished data); however, these mass spec experiments 
were not quantitative.  Any observed reduction in interactions with Nkx2.2-SDmutant protein 
compared to Nkx2.2-WT protein must be confirmed through other methods.  Co-
immunoprecipitation experiments can be conducted to confirm these interactions, and 
requirement for the SD domain can be assessed. 
Future experiments can also dissect the role of the SD domain in mature beta cells.  The MIP-
CreER allele can be used to distinguish between SD domain function during beta cell maturation 
and in fully mature beta cells (Wicksteed et al., 2010).  The RIP-Cre allele used in βSD mice is 
activated shortly after beta cell formation and therefore cannot distinguish between these two 
stages.  If the primary function of the SD domain is to mediate interaction with Dnmt1 to 
maintain epigenetic information during proliferation, perhaps mice with the MIP-CreER would 
no longer display metabolic defects since adult beta cells are primarily quiescent.  However, 
these mice may display defects when challenged with high fat diet (HFD) or pregnancy, since 
these conditions stimulate beta cell proliferation (Bouwens and Rooman, 2005), and may reveal 
defects in the propagation of epigenetic marks. 
Mouse models of diabetes can involve loss of beta cell function (Guo et al., 2013; Talchai et al., 
2012).  This analysis of Nkx2.2 SD domain function has given us a better understanding of the 
mechanisms required to establish and maintain beta cell fate.  Similar mechanisms may be 







Diabetes is a serious condition involving beta cell dysfunction and loss of glycemic control; this 
disease is increasing in prevalence worldwide (IDF, 2015).  A current area of therapeutic 
research has focused on the in vitro differentiation of pancreatic beta cells, with the goal of 
transplanting these cells back into patients to restore glucose homeostasis.  In this thesis work, a 
critical window for beta cell specification has been identified, with a unique requirement for the 
transcription factor Nkx2.2.  In addition, co-occupancy between Nkx2.2, Rfx6, and NeuroD1 at 
endocrine-related genes suggests novel cooperation among these beta cell transcription factors.  
Rather than functioning in a strict hierarchy, there may be combinatorial functions that are 
necessary for endocrine commitment.  Lastly, the SD domain of Nkx2.2 protein appears to not 
only be involved in early regulation of pancreatic specification genes, but also within the beta 
cell for maintenance of beta cell fate.  These studies provide a better understanding of pancreatic 
beta cell differentiation and also the mechanisms involved in maintaining beta cell function.  
These in vivo mechanisms may prove to be important for the optimization of in vitro beta cell 
differentiation protocols and successfully maintaining beta cell function following beta cell 
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